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Abstract
Early infantile epileptic encephalopathy (EIEE) and early myoclonic encephalopathy
(EME) are catastrophic epilepsies starting in the neonatal period. The International
League Against Epilepsy classifies both of them as generalized symptomatic epilepsies
of nonspecific etiology, characterized by early onset,  presence of burst-suppression
EEG  pattern  and  serious  prognosis.  The  critical  difference  lies  in  their  presumed
etiologies and the prevailing clinical seizure type at onset: EIEE (known as Ohtahara
syndrome) usually manifests with tonic seizures, while EME is mainly associated with
myoclonic seizures. However, the distinction between those two pathologies is not
always easy due to clinical and etiological overlap. Both mutations in the ARX gene
for EIEE (OMIM 308350) and disruption in the neuregulin receptor ErbB4 for EME
(OMIM 609304) impair interneuron migration and alter the number of GABAergic
interneurons in the postnatal cortex. These findings could explain the occurrence of
severe  epileptic  encephalopathy  with  a  burst-suppression  pattern  and represent  a
continuum of  progressive  pathology.  In  the  present  chapter  we  review the  genes
involved in EIEE and EME including their possible mechanisms of action, particularly
via  GABAegic  interneurons.  Their  clinical  manifestations  are  myoclonic  or  tonic
seizures, which represent the expression of the underlying pathology and correlate
with degree of brain damage.
Keywords: ARX gene, burst-suppression EEG pattern, early infantile epileptic ence-
phalopathy, early myoclonic encephalopathy, early-onset epileptic encephalopathy,
encephalopathy, epilepsy, ErbB4, GABA, interneurons, genetics, development, chil-
dren, neonatal epilepsies, newborn, Ohtahara syndrome, seizures
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1. Introduction
Neonatal  seizures  are  the  most  characteristic  sign  of  neurological  disease  and the  most
frequent neurological events during the neonatal period (babies less than 28 days old), often
reflecting a  variety of  different  pre-,  peri-,  or  postnatal  disorders  of  the central  nervous
system (CNS). The incidence of seizures is highest during the neonatal period. The overall
risk of neonatal seizures in the United States was 2.84 per 1000 live births, and risk estimates
were consistently higher in low-birth-weight infants (relative risk of 3.9) [1]. We have found
an absolute incidence of neonatal convulsions in newborns (NBs) infants of 2‰ in live births
(in full term of 1.4‰, in preterm of 13.4‰, and in immature NBs (with a gestational age of
<29 weeks) of 27.8‰) [2]. Besides, higher incidence and prevalence rates of epilepsy have
been found in developing countries [3]. They may be symptomatic or cryptogenic, precur-
sory or subsequent epilepsies, and acquired causes are the most frequent. Thus, in our study
the etiology was distributed as follows: hypoxic-ischemic encephalopathy (HIE, 32%), brain
malformations  or  cerebral  dysgenesis  (24%),  intracranial  hemorrhage  (16%),  and,  less
frequently, infections, metabolic disorders and pharmacological changes (8%), and epilep-
togenic diagnosis (4%). Notwithstanding, we are currently observing a decrease down to
7.9%  in  brain  malformations  as  a  cause  of  neonatal  seizures  due  to  the  impact  of  the
implementation of the legal termination of pregnancy due to congenital anomalies or birth
defects.
The neonatal period is the most vulnerable time for the occurrence of seizures. Overall,
neonatal seizures are the expression of a serious neurological condition that requires urgently
both etiological and symptomatic treatment, because by themselves can aggravate brain
damage. The study of neonatal seizures also allows us to better understand the mechanisms
that affect the developing brain [4]. The burden of acute recurrent seizures in neonates may
also impact chronic outcomes independently from the etiology [5].
The developing brain has a higher incidence of seizures in both animal and human models.
These neonatal seizures can produce long-lasting consequences that are stage-dependent [6].
The nervous system (NS) of the newborn presents singularities related to the lower maturation
of its structures. The neonatal brain has an increased neuronal metabolism, and, therefore, a
high rate of oxygen consumption. Such energetic costs seem also to exert a selective pressure
toward a metabolically efficient neural morphology, leading to a metabolically efficient
patterning of dendritic arborizations, neural codes, and brain-wiring patterns [7]. However,
the theory of energy failure has largely been disproved. Brains of immature animals have been
shown to be capable of using anaerobic metabolism and require less adenosine triphosphate
(ATP) when aerobic energy production ceases, even during status convulsive. Recent explan-
ations for the injurious consequences of prolonged convulsions postulate that neuronal
damage occurs from excessive release of excitatory amino acids (EAA) which, by binding to
their ligand-gated ionic receptors, cause a large influx of Ca2+, resulting in acute excitotoxic cell
death and neuronal apoptosis [8].
On the other hand, neurotransmitters (NTs)—especially γ-aminobutyric acid (GABA) and
glutamate—as well as N-methyl-D-aspartate receptors (NMDARs) play key roles in successive
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steps of brain development, including the proliferation, migration, survival, and differentia‐
tion of neurons. Cerebral cortical circuits are composed of both excitatory (glutamatergic)
projection and local inhibitory (GABAergic) neurons. The NMDA receptor subunits in the
developing brain are more permeable and less susceptible to block than mature forms, with
the result that immature brains are far more excitable and epileptogenic than the adult brain
(9). Although in general the neonatal brain is more resistant to hypoxia than the adult brain,
the former seems to be more vulnerable to the neurotoxic amino acids that occur during
seizures [9].
Although early‐onset epileptic syndromes are a rare and not a common cause for neonatal
seizures, they have aroused increasing interest since they generally involve genetic diseas‐
es. Thus, it is very important to establish the diagnosis in order to allow adequate genetic
counseling. The study of these syndromes has also helped to clarify the role of NTs and
receptors, signal transduction, intracellular transporters, and enzymes in the origin of seiz‐
ures. More accurate molecular genetics diagnostic tools will allow diagnosing a larger
number of cases previously considered of unknown etiology and open the door to phar‐
macogenomics.
2. Neonatal epileptic encephalopathy (EE) with suppression-burst EEG
pattern
2.1. Concept of epileptic encephalopathies
The International League Against Epilepsy (ILAE) defines epileptic encephalopathies (EEs) as
follows: they “are a group of diseases in which epileptic activity itself contributes to severe
cognitive and behavioral impairments above and beyond what might be expected from the
underlying pathology alone. These impairments can worsen over time” [10]. This means that
not only refractory seizures but also that serious epileptiform discharges observed in the
electroencephalogram (EEG) background contribute to the progressive decline in brain
function. The three main features of EEs are refractory seizures, severe EEG abnormalities,
developmental delay, and/or intellectual disability. Around 40% of seizures that occur during
the first 3 years of life are due to EEs. A few syndromes are considered epileptic encephalo‐
pathies, also known as early‐onset epileptic encephalopathies (EOEEs) (for a review, see [11,
12]):
– Early myoclonic encephalopathy (EME) and Ohtahara syndrome (OS) in the neonatal
period;
– West syndrome (WS), epilepsy of infancy with migrating focal seizures (EIMFS), and
Dravet’s syndrome (DS) during infancy;
– Lennox‐Gastaut syndrome (LGS), epileptic encephalopathy with continuous spikes and
waves during sleep (CSWS), and Landau‐Kleffner syndrome (LKS) during childhood.
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2.2. Classification epilepsy syndromes
In the last International Classification of the Epilepsies (ILAE classification), the epilepsy
syndromes are classified by reliably identified common clinical and electrical characteristics.
Such “electro-clinical” syndromes have a typical age of seizure onset, specific seizure types,
and EEG characteristics, and often other features, which when taken together allow the
diagnosis of every specific epilepsy syndrome [13]. The classification, which has been updated
on an ongoing basis by the ILAE Commission on Classification and Terminology in Epilepsy
Diagnosis [14] (a cutting-edge online diagnostic manual of the epilepsies), includes within the
electro-clinical syndromes of neonatal/infantile onset the following syndromes (arranged by age
at onset):
2.2.1. Neonatal period
• Self-limited neonatal seizures and self-limited familial neonatal epilepsy
• Early myoclonic encephalopathy (EME)
• Ohtahara syndrome (OS) or early infantile epileptic encephalopathy (EIEE)
2.2.2. Infancy
• Self-limited familial and nonfamilial infantile epilepsy
• West syndrome (WS)
• Dravet’s syndrome (DS)
• Myoclonic epilepsy in infancy (MEI)
• Epilepsy of infancy with migrating focal seizures (EIMFS)
• Myoclonic encephalopathy in nonprogressive disorders
• Febrile seizures plus, genetic epilepsy with febrile seizures plus
“Early myoclonic encephalopathy” (EME) and “Ohtahara syndrome” (OS), are listed as two
separate syndromes in the classification of epilepsies. Both are characterized by early onset
(EIEE may also occur later), presence of “burst-suppression” (BS) EEG pattern, seizures that
do not respond to anti-seizure medication, and serious prognosis. EEG pattern is the most
important diagnostic feature for both clinical entities. BS means that the EEG tends to display
periods of very little electrical brain activity or flattening of the brain waves, followed by a
burst of high spiky activity before returning to very low activity again. The BS is characterized
by high-voltage bursts (multifocal spikes of 150–350 mV, and 1–3-s duration) alternating
regular rate with almost flat suppression phases (2–5 s). These changes can be seen both during
sleep and when the child is awake [15]. The differential diagnosis is based mainly on the
different types of seizures: fragmentary myoclonus, erratic focal seizures, and massive
myoclonias for EME, and tonic seizures and predominantly tonic spasms (flexor or extensor/
stiffening of arms or legs, uni-, or bilateral) for EIEE [16, 17] (see Table 1).
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Early myoclonic encephalopathy (EME) Early infantile epileptic encephalopathy
(EIEE) Ohtahara syndrome
General description • Both entities are syndromes consisting of frequent intractable seizures and severe early
encephalopathy resulting in limited development and reduced life expectancy.
• They are considered “epileptic encephalopathies”. This term implies that the epileptic
activity itself might be directly implicated in additional neurodevelopmental impairments
besides those expected from the underlying etiology alone, and that suppression of
epileptic activity might minimize this additional disability.
• Treatable metabolic etiologies (especially pyridoxine and pyridoxal-5-phosphate
disorders) should be excluded early.
• Both sexes are affected equally.
Age of occurrence Onset of seizures in the first 2 months of life
(during the first week in 76% of the
cases, with 96% occurring by the first month)
The onset of seizures is in the first month of
life (range 1–3 months).
Different seizure types Myoclonic seizures are frequent:
fragmentary myoclonus, erratic focal
seizures, and massive myoclonias.
Tonic seizures are observed later,
usually around 3–4 months of age.
Tonic seizures predomínate.
Many seizure types may occur, but
myoclonic seizures are rare.
Electroencephalograph Suppression-burst pattern: Consisting of alternating periods of slow waves of high
amplitude (the burst) and periods of so-called flat EEGs (the suppression)
Clinical course Severe developmental delay is seen, with or without regression.
Children with this syndrome may evolve to
West or Lennox Gastaut syndrome.
Antecedent and birth
history
Typically normal
Neurological examination Abnormal neurological behavior may be present prior to onset of seizures.
Abnormal in keeping with the presence of
severe neurological impairment.
Head size is typically normal at onset;
microcephaly may develop over time.
Abnormal in keeping with underlying brain
structure abnormalities and the presence of
severe neurological impairment.
Head size is typically normal; however,
microcephaly may occur.
Causes:
There is overlap in the
etiologies that cause
Ohtahara syndrome and
early myoclonic
encephalopathy.
Metabolic etiologies are common (nonketotic
hyperglycinemia is the commonest cause,
amino and organic acidopathies, urea cycle
disorders, mitochondrial disorders,
pyridoxine and pyridoxal-5-phosphate
disorders, molybdenum cofactor deficiency,
Structural brain etiologies are common
Metabolic etiologies (mitochondrial
disorders, nonketotic hyperglycinemia,
pyridoxine/pyridoxal-5-phosphate
disorders, carnitine palmitoyl transferase
deficiency, and others).
GABAergic Interneurons in Severe Early Epileptic Encephalopathy with a Suppression-Burst Pattern: A Continuum...
http://dx.doi.org/10.5772/64458
49
Early myoclonic encephalopathy (EME) Early infantile epileptic encephalopathy
(EIEE) Ohtahara syndrome
sulfite oxidase deficiency, Menke syndrome,
Zellweger syndrome, and other
disorders are also seen). Structural brain
abnormalities are rare.
Genetic causes SLC25A22, ErbB4, etc. ARX, STXBP1, KCNQ2, SCN2A, GNAO1,
etc.
Table 1. Epilepsy syndromes with debut neonatal/infantile and suppression-burst EEG pattern.
2.3. Early myoclonic encephalopathy (EME)
EME was first reported in 1978 by Aicardi and Goutieres [18], as “Encephalopathie myoclo-
nique neonatale”. It is characterized by early-onset fragmentary myoclonus, erratic focal
seizures, and massive myoclonias during the neonatal period (before the first week 76% of the
cases, and 96% occurring within the first month). Tonic seizures are observed later, generally
around 3–4 months of age [16, 19]. Suppression-burst pattern (SBP) becomes more apparent
in sleep in EME. The prognosis is grave [20] and evolves into hypsarrhythmia in 41% of
patients [21].
2.4. Early infantile epileptic encephalopathy (EIEE), and Ohtahara syndrome (OS)
OS is also known as “early infantile epileptic encephalopathy” (EIEE) or “early infantile
epileptic encephalopathy with burst-suppression pattern”. EIEE was first described by
Ohtahara and contributors in 1976 [22], mainly characterized by tonic spasms that start during
the first month of life (range of 1–3 months, but may occur within the first 10 days of life or
during the first hour after delivery). The epileptic spasms may be either generalized and
symmetrical or lateralized, and may occur in clusters or singly, while awake and during sleep
alike. The duration of tonic spasms is up to 10 s, and the interval between spasms within cluster
ranges from 9 to 15 s. In one-third of cases, other seizure types include partial motor seizures
or hemiconvulsions, but myoclonic seizures are rare [23]. Interictal EEG shows a BS with high-
voltage paroxysmal discharges separated by prolonged periods of nearly flat tracing that last
for up to 18 s. OS is considered to be the result of developmental static structural brain damage.
Patients show a poor outcome with severe psychomotor retardation or death. In the majority
of patients (76%), EIEE evolves to infantile spasms (ISS) [21].
2.5. Severe early-onset epileptic encephalopathy (EOEEs) with a suppression-burst pattern:
a continuum of pathology
Ohtahara and Yamatogi in 2006 [24] explain the differential diagnosis of EME versus EIEE/OS.
Etiologically, structural brain lesions are most likely in OS, and nonstructural/metabolic
disorders in EME. Clinically, tonic spasms are the main seizures in OS, while myoclonia and
frequent partial motor seizures in EME. Another difference is noted in th EEG findings: SBP
is consistently observed in both waking and sleeping states in OS, but SBP becomes more
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apparent during sleep in EME. In OS, the SBP evolves to hypsarrhythmia around 3–4 months
of age, and sometimes it progresses further to diffuse slow spike waves; by contrast, in EME
the SBP may persist up to late childhood after a transient evolution to hypsarrythmia in the
middle to late infancy. The evolution of the two syndromes is also different: OS evolves to West
syndrome (WS), and further to Lennox-Gastaut syndrome (LGS) with age, but EME persists
long without such an evolution except a transient phase of West syndrome.
Nevertheless, the border between the two syndromes unfortunately is not always clear since
they share many common features (age of onset, BS-EEG pattern, grave prognosis), but also
each of them can evolve from one to the other. Due to this overlap, the classification is
sometimes questionable even among the published cases. Thus, they have also been generally
referred to as “neonatal epileptic encephalopathy” [25]. To the point that Aicardi and Ohtahara
finally recognized that they may be one single epileptic syndrome, and they proposed the
designation of “severe neonatal epilepsies with suppression-burst pattern” [16]. Various
authors have also suggested that both entities constitute a single syndrome that has a predict-
able age-related evolution and its clinical manifestations express a continuum of the progres-
sive brainstem dysfunction, with frequent evolution toward West and Lennox-Gastaut
syndromes [21, 26, 27].
The severe epileptic encephalopathies (EIEE, WS, late infantile epileptic encephalopathy, and
LGS) share many common clinical features and in certain individuals there is a progression
from one syndrome to the next. Ohtahara proposed that these epilepsies occur on an electro-
clinical spectrum and that the clinical and EEG features depend on the maturity of the NS [28].
However, there are differences between the disorders that may not be explained by the concept
of “age-dependent encephalopathy” [29]. Other authors such as Lombroso [30] conclude that
there is some justification to provisionally support a nosological place for the EME syndrome,
whereas a nosologically separate position for the EIEE syndrome seems to be less justified, and
it would be safer to consider it for now as an early variant of the West syndrome (WS).
Most of the cases of EIEE are associated with structural brain anomalies while the better part
of EME with metabolic disorders (including nonketotic hyperglycinemia) [16, 20, 30–33].
Nevertheless, the etiology of EIEE is heterogeneous, and patients with EIEE often have
acquired causes (e.g., HIE), structural brain defects (e.g., cortical brain malformations), or
metabolic disorders [34, 35]. Thereby, the recognition is that multiple etiologies can produce
under certain circumstances either syndrome, and there is an overlap in both severe early-
onset epileptic encephalopathies (EOEEs) that may share a common mechanism. On the other
hand, recent molecular genetics studies have shown that these encephalopathies are geneti-
cally heterogeneous and phenotypically diverse disorders, such that similar gene mutations
have been found in several different epileptic encephalopathies syndromes, reinforcing the
notion that these epilepsies are unlikely to be distinguished on the basis of cause alone. Thus,
the ILAE emphasizes in its classification the symptomatic nature and nonspecific etiology of
these syndromes.
Lombroso et al. found that asphyxiated babies meeting EME criteria exhibited both erratic
myoclonia and BS, while presenting clinical and EEG parameters and evolutions differing from
others who had homogeneous enough profiles to justify their inclusion in a provisional EME
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syndrome [8]. However, since HIE can be the common cause of neonatal seizures, brain
damage, and BS pattern (BS is caused in 44.1% of cases by HIE) [36], it may serve as a model
to study the correlation of progressive brain damage and evolution of the crisis. In our clinical
experience, we have observed that the two entities (EME and EIEE) may be present in the
evolutionary course of an epileptogenic encephalopathy neonatal secondary to HIE. As an
illustrative example, we report the case of a newborn infant admitted to the Pediatrics
Department at the Albacete General Hospital (Spain), who initially presented early neonatal
seizures as tonic extension of the limbs, eye deviation, as well as sucking, pedaling, and
swimming movements. Their initial EEG showed severe depression of brain bioelectrical
activity, which progressed into EME at 15 days, with myoclonic convulsions and a BS-EEG
pattern. Neuroimaging studies objectified a deep ischemia with the involvement of basal
ganglia. Within 2 months of life, the clinical picture changed and it was suggestive of EIEE:
flexion spasms appeared together with radiological progression toward a “multicystic
encephalomalacia”. In our patient, the presence of myoclonic seizures with subsequent flexion
spasms associated with the appearance of brain structural abnormalities and the persistence
of a BS-EEG pattern also support the notion of one epileptic syndrome with different clinical
manifestations depending on age at presentation and brain damage/maturational status of the
patient.
We have also observed the clinical course and EEG evolution of an extreme low-birth-weight
preterm neonate with glycine encephalopathy (already published [37]), in which the BS pattern
and seizures did not appear until the third month after birth (40 weeks corrected gestational
age). An immature brain could have been responsible, at least in part, for the long asympto-
matic period before the onset of convulsions in our patient. This suggests that an adequate
maturation and organization of the brain development—particularly regarding GABAergic
interneurons—is required for the onset of EME.
The most prominent distinctive points between both epilepsy syndromes are the observation
that patients with OS exhibit predominantly tonic seizures, their crises evolve to ISS, and the
outlook is often worse than in patients with EME. Although both syndromes may have
different courses, the differentiation at the beginning may be impossible, since both myoclonus
and tonic convulsions may coexist and present the same electrical pattern, although some
specialists report to be able to find distinctive features between the EEG patterns. Tonic seizures
are considered to be a manifestation of brainstem dysfunction and it is possible that this is
more prominent in OS. Thereby, in a review article Djukic and collaborators [21] analyze
preliminary studies that would suggest the following:
– Evidence that the brainstem is involved in the expression of tonic seizures;
– Evidence of increased excitability/epileptogenicity in the immature brainstem;
– Evidence of decreased seizure-controlling substrate in the immature brainstem;
– Clinical evidence supporting the notion that tonic seizures are associated with the severity
of brainstem dysfunction in EIEE and EME;
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– For the Ohtahara syndrome, some mothers retrospectively reported movements consis-
tent with seizures in utero [38]. Unable to rule out that the myoclonic component had
occurred in utero.
The standard notion is that when the brain is intact and a strong harmful event happens leading
to acute excitotoxic cell death and neuronal apoptosis (e.g., acute cerebral injury in HIE and
metabolic disorders), a BS-EEG pattern is acutely developed. However, the newborn shows a
first stage of frequent and diverse seizure types: fragmentary myoclonus, erratic focal seizures,
and massive myoclonias compatible with the specific epilepsy syndrome EME. Conversely,
when there is brain damage established—nonprogressive static structural developing brain
damage (e.g., brain injury such as as multicystic encephalomalacia in HIE, cortical brain
malformations, brainstem dysfunction, and metabolic disorders with intrauterine brain
damage, among others)—also a BS-EEG pattern may occur that can be demonstrated, but the
infant is more likely to show tonic intractable seizures that are typical of EIEE. In view of these
evidences, we believe that these syndromes do not correspond so much to an “age-dependent
encephalopathy” but rather to a “damage-dependent encephalopathy”. Thereby, it is possible
that these syndromes represent successive stages of “a continuum and progressive neuronal
injury” from an epileptic process.
3. Genetic factors in severe early-onset epileptic encephalopathy
3.1. Genome instability and neurotransmitter signaling
The genetic factors are thought to play a role in at least 70% of patients with epilepsy [39].
Genetic analysis for copy number variants (CNVs) and single EOEEs candidate genes have
become increasingly important investigations in clinical practice. Data suggest that mutations
causing EE are often sporadic, mostly due from de novo dominant mutations in a single
autosomal gene, although inherited autosomal recessive and X-linked forms also exist [40].
Over recent years, huge steps have been made to clarify the genetics of epilepsy, and the
amount of reports on novel genetic causes of EOEEs has increased due to fast developments
and dramatically reduced costs in molecular genetic techniques, especially the “next-genera-
tion sequencing” (NGS) technologies (for a review, see [41–43]).
Mutations have been identified in several genes in infants with severe EOEEs, clustering in
several biological pathways that are often shared by patients with similar mutations. But the
complexity of phenotype/genotype correlations—one syndrome having multiple genetic
causes (genetic heterogeneity) and one gene being associated with different phenotypes
(pleiotropy)—has been progressively unraveled for both EIEE and EME. To date, the genetic
origin of up to 36 genetic phenotypes (EIEE 1 to EIEE36), as referred in the Online Catalog of
Human Genes and Genetic Disorders “Online Mendelian Inheritance in Man” (OMIM), has
been identified [44]. Many of them are related to mutations in NT receptors, transporters, or
associated proteins.
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Title (OMIM) Gene Phenotype Clinical Age Seizures predominate EEG
EIEE1
(308350) 
ARX  Ohtahara syndrome  1–3 months  Tonic seizures  SBP 
EIEE2
(300672) 
CDKL5  X-linked dominant infantile
spasm syndrome-2 (ISSX2).
Dysmorphic. 
1–10 weeks  Infantile spasms.
Atypical Rett
syndrome 
H 
EIEE3
(609304) 
SLC25A22 Early myoclonic
encephalopathy (EME) 
Neonatal period  Myoclonic seizures  SBP 
EIEE4
(612164) 
STXBP1  Ohtahara and West syndrome
with cerebral hypomyelination 
3 days to 4.5
months 
Tonic seizures  SBP/H 
EIEE5
(613477) 
SPTAN1  West syndrome with
pontocerebellar atrophy and
hypomyelination 
3 months  Infantile spasms.  H 
EIEE6
(607208) 
SCN1A  Dravet S. and FEB3A, MHP3  Mean 6 months  Multiple types.  GSWD 
EIEE7
(613720) 
KCNQ2  Ohtahara Syndrome and
BFNS1 
Neonatal period  Tonic seizures  SBP 
EIEE8
(300607) 
ARHGEF9 Hyperekplexia and epilepsy  Neonatal period  Tonic seizures
provoked by tactile
stimulation 
Varies 
EIEE9
(300088) 
PCDH19  EFMR. Juberg-Hellman
syndrome 
6–36 months  Multiple types  Varies 
EIEE10
(613402) 
PNKP  Microcephaly, seizures, and
developmental delay (MCSZ) 
<6 months  Complex partial
type 
Varies 
EIEE11
(613721) 
SCN2A  EIEE and benign familial infantile
seizures-3 (BFIS3) 
Neonatal period  Tonic-clonic seizures.
Infantile spasms 
SBP
GSWD 
EIEE12
(613722) 
PLCB1  West Syndrome and MMPSI  10 weeks to 6
months 
Tonic seizures/infantile
spasms 
MF/H 
EIEE13
(614558) 
SCN8A  Intractable seizures  First days to 6
months 
Multiple types  Varies/H 
EIEE14
(614959) 
KCNT1  Refractory focal seizures.
MMPSI 
<6 months  Multiple types  MF 
EIEE15
(615006) 
ST3GAL3  West syndrome  3–7 months  Infantile spasms  H 
EIEE16
(615338) 
TBC1D24  Familial infantile myoclonic
epilepsy (FIME) and MMPSI 
First weeks or
months 
Myoclonic seizures.
Multiple types 
Varies 
EIEE17
(615473) 
GNAO1  Intractable seizures  First weeks or
months 
Tonic seizures  SBP 
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Title (OMIM) Gene Phenotype Clinical Age Seizures predominate EEG
EIEE18
(615463) 
SZT2  Dysmorphic feature and thick
corpus callosum 
First months or
years 
Tonic-clonic seizures  Varies 
EIEE19
(615744) 
GABRA1  Dravet syndrome  8–11 months  Multiple types  GSWD 
EIEE20
(300868) 
PIGA  Multiple congenital
anomalies—hypotonia-seizures,
Syndrome 2 
First days to 9
months 
Myoclonic seizures  SBP/H 
EIEE21
(615833) 
NECAP1  Intractable seizures  First years  Multiple types  Varies 
EIEE22
(300896) 
SLC35A2  Congenital disorder of
glycosylation type IIm
(CDG2M) 
First days to 3
months 
Tonic seizures.
Infantile spasms 
Varies/H 
EIEE23
(615859) 
DOCK7  Intractable seizures.
Dysmorphic feature and
cortical blindness 
2–6 months  Tonic seizures.
Multiple types 
MF/H 
EIEE24
(615871) 
HCN1  Resembling Dravet syndrome
with pharmacoresistant febrile
seizures 
4–13 months  Tonic-clonic, progress
to atypical absences 
Varies 
EIEE25
(615905) 
SLC13A5  Developmental delay and tooth
hypoplasia 
First 7 days  Focal clonic seizures.
Status epilepticus 
Focal MF 
EIEE26
(616056) 
KCNB1  Intractable seizures  First years  Multiple types  H/MF 
EIEE27
(616139) 
GRIN2B  West syndrome  First months  Infantile spasms  H 
EIEE28
(616211) 
WWOX  Lethal microcephaly syndrome.
Simplified gyral pattern 
Mean 2 months  Multiple types  Varies 
EIEE29
(616339) 
AARS  Hypomyelination. Charcot-Marie-
Tooth disease, axonal, type 2N 
3–6 months  Myoclonic seizures  MF 
EIEE30
(616341) 
SIK1  Intractable seizures  Neonatal period  Myoclonic. Tonic and
infantile spasms 
SBPMF
H 
EIEE31
(616346) 
DNM1  Intractable seizures. West
syndrome 
2–13 months  Multiple types.
Infantile spasms 
Varies/H 
EIEE32
(616366) 
KCNA2  Ataxia and myoclonic epilepsy  5–17 months  Myoclonic seizures.
Multiple types 
Varies 
EIEE33
(616409) 
EEF1A2  West syndrome  First week or
month 
Myoclonic seizures.
Infantile spasms 
MF/H 
EIEE34
(616645) 
SLC12A5  Refractory migrating focal
seizures 
First weeks or
months 
Focal seizures  Varies 
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Title (OMIM) Gene Phenotype Clinical Age Seizures predominate EEG
EIEE35
(616647) 
ITPA  Lack of myelination of early
structures 
Neonatal period  Multiple types  Varies 
EIEE36
(300884) 
ALG13  Congenital disorder of
glycosylation Is 
First week or
month 
Infantile spasms  MF/H 
SBP: suppression-burst pattern on EEG. H: hypsarrhythmia. GSWD: generalized spike-wave discharges. MF:
multifocal epileptogenic foci. MMPSI: malignant migrating partial seizures of infancy. FEB3A: febrile seizures,
familial, 3A. MHP3: migraine, familial hemiplegic, 3. BFNS1: benign familial neonatal seizure 1. EFMR: epilepsy,
female-restricted, with mental retardation.
Table 2. EIEE following the classification of OMIM.
Despite these evidences, in the last International Classification of epilepsies these entities are
included as epilepsy syndromes and they are classified according to the age of onset and their
electro-clinical features, for example, Ohtahara and West syndromes. However, in OMIM these
syndromes are included in the so-called “epileptic encephalopathy, early infantile”, or “early
infantile epileptic encephalopathy” (EIEE), paying great attention to their genetic origin and
less so to their phenotype. Thus, epileptic encephalopathy, early infantile 1 (EIEE1) is Ohtahara
syndrome (OMIN 308350) caused by a mutation in the “aristaless-related homeobox gene”
(ARX; 300382) on chromosome Xp22. Whereas early myoclonic encephalopathy (EME; OMIM
609304) caused by mutation in the “solute carrier family 25 (mitochondrial carrier, glutamate),
member 22 gene” (SLC25A22; 609302), is named EIEE3 (609304) Dravet’s syndrome, caused
by mutation in SCN1A gene (182389), is named EIEE6 (6070208) (see Table 2).
Nevertheless, the heterogeneity of the epileptic features is often the rule for most of the
reported genes, and, inversely, the same gene mutation can cause several seizure types, even
in the same patient across ages. Therefore, in many cases, clinical prediction of causative genes
is challenging for some patients, since the association between phenotypic pleiotropy and
genetic heterogeneity phenotype is not sufficiently distinctive. Sequential single-gene analysis
(by direct Sanger sequencing) is costly, time consuming, and often unsuccessful. With the
current development of the NGS technologies—via gene panel analysis—diagnostic rates
improve. NGS can also help to clarify and broaden the phenotypic spectrum of the genes
involved. In a recent study, Trump et al. [45], in a 400 series of patients with early-onset seizure
disorders and/or severe developmental delay, identified causative mutations in 18% of the
individuals with seizures. The diagnostic rate was highest among those with seizure onset
within the first 2 months of life (39%). The most frequently mutated gene was SCN2A (11
patients). Other recurrently mutated genes included CDKL5, KCNQ2, SCN8A (six patients
each), FOXG1, MECP2, SCN1A, STXBP1 (five patients each), KCNT1, PCDH19, TCF4 (three
patients each), and ATP1A3, PRRT2, and SLC9A6 (two patients each). Mutations in EHMT1,
GABRB3, LGI1, MBD5, PIGA, UBE3A, and ZEB2 were each found in single patients. These
authors also pointed out that only in 15% of them, the clinician had sufficient clinical certainty
for a specific mutated gene as the probable cause prior to genetic testing. Neurometabolic
disorders and frequent major structural brain anomalies were not included in the panel, which
may explain the absence of the ARX gene.
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3.2. Genetic mutations in Ohtahara syndrome
A phenotype relatively similar to that of Ohtahara syndrome can be a consequence of various
mutations on a single gene, with special mention to the ARX gene, but also to KCNQ2, SCN2A,
STXBP1, and GNAO1 among other genes.
3.2.1. The homeobox gene ARX (MIM 300382)
One of the most important and well studied is the mutation in the ARX gene, which is the one
responsible for OS named EIEE1 (OMIM 308350) that causes severe disorganization of
forebrain with aberrant migration and differentiation of interneurons containing gamma-
aminobutyric acid (GABAergic interneurons) [46–49] via the Dlx pathway [50]. Additionally,
the ARX gene modifies glutamatergic neurons excitability and morphology. Pyramidal
neurons show a dramatic rise in the frequency of excitatory inputs associated with a redevel-
opment of their axonal arborization resulting from glutamate network remodeling. Thus,
secondary alterations are instrumental for the development of disease-specific phenotypes and
should be regarded to explain the “phenotypic pleiotropy” associated with epileptogenic
mutations [51].
The homeobox gene ARX is one of the most frequently mutated genes in “phenotypic spectrum
of disorders”, comprising a nearly continuous series of X-linked developmental disorders with
intellectual disability (ID), ranging from syndromic (S-XLMR) and nonsyndromic X-linked
mental retardation (XLMR), to lissencephaly and infantile spasms without brain malforma-
tions. At least seven well-defined clinical entities have been described including [47, 52, 53].
– Ohtahara syndrome (308350),
– Nonsyndromic X-linked mental retardation with or without seizures, ARX-related
(OMIM 300419),
– Partington syndrome, characterized by the association of mild to moderate intellectual
deficit, dysarthria, and variable movement disturbances—dystonic hand movements—
(OMIM 309510),
– Proud syndrome or microcephaly—corpus callosum agenesis—abnormal genitalia
syndrome (OMIM 300004),
– X-linked lissencephaly with ambiguous genitalia (LISX2, XLAG), as well as hydranence-
phaly and abnormal genitalia (OMIM 300215).
The genetic heterogeneity (same clinical entities being associated with several mutations in
ARX) together with intra- and interfamilial pleiotropy is becoming a hallmark of ARX
mutations [53]. It appears to be a consistent genotype-phenotype correlation and both intra-
and interfamilial variability of expression of some of the mutations, particularly the common
428-451dup (24 bp) mutation [54]. On the other hand, brain-imaging abnormalities can also be
highly variable, ranging from lissencephaly/hydranencephaly and cortical dysplasia (among
others) to normal brain. Microarray analysis has identified a total of 1006 gene promoters
bound by ARX, and around 24% of Arx-bound genes were found to show expression changes
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following ARX overexpression or knock-down. Several of the ARX target genes are known to
be important for a variety of functions in brain development and some of them suggest new
functions for ARX [55]. Phenotype/genotype studies in humans suggest that truncating
mutations cause X-linked lissencephaly, and insertion/missense mutations result in epilepsy
and intellectual deficit without cortical dysplasia [56].
3.2.2. Dysfunctions of potassium (K+) channels
Several epileptic phenotypes have been associated to dysfunctions of potassium (K+) channels,
and it has been recently proposed to name such epilepsies as “K+ channelepsies” [57]. Based
on their structures, biophysical characteristics, pharmacological sensitivities, and physiology,
these channels are classified as (for a review, see [58]) follows:
– Voltage-gated (Kv 1-12): Regulation of outward K+ currents and action potentials,
modulation of NT release, control of both excitability and electrical properties of neurons.
– Inwardly rectifying (Kir1-7): Maintenance of the resting membrane potentials and
regulation of the cell excitability.
– Sodium-activated channels (KNa): Regulation of delayed outward currents IKNa and
contribution to adaptation of firing rate.
– Ca2+-activated channels (KCa): Regulation of neuronal firing properties and circuit
excitability.
3.2.2.1. KCNQ2 (# 602235)
As an example of phenotypic diversity, reference is made to mutation in the KCNQ2 gene on
chromosome 20q13.3 (encoding the Kv7.2 channel), characterized by benign familial neonatal
seizures-1 (BFNS1) that can also cause early infantile epileptic encephalopathy-7 (EIEE7,
OMIM 613720). Reported genotype-phenotype observations for KCNQ2 with truncating
mutations are associated with the benign, inherited phenotype and missense mutations
affecting key residues with the severe, sporadic phenotype [45]. Cellular experiments indicate
that these latter mutations may have a dominant negative effect on cellular function [59].
The EIEE7 is an atypical severe early-onset epilepsy with refractory seizures and prominent
tonic component. Most patients showed a BS-EEG pattern and were diagnosed clinically with
Ohtahara syndrome (but with an earlier start during the neonatal period), infrequent evolution
to West syndrome, and good response to sodium channel blockers (phenytoin, carbamazepine,
zonisamide,…), topiramate (TPM), or valproic acid, but poor developmental prognosis [60].
Weckhuysen et al. in 2012 [61] reported eight unrelated patients with EIEE7 confirmed by
genetic analysis. All patients had the onset of seizures during the first week of life, and two
mothers retrospectively noted intrauterine jerking during the last 2 months of pregnancy. Early
magnetic resonance imaging (MRI) of the brain showed characteristic hyperintensities in the
basal ganglia and thalamus. These evidence supports (as we mentioned above) that the
myoclonic component had occurred in utero while tonic crises may be a manifestation of
brainstem dysfunction [21].
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3.2.2.2. KCNT1
The KCNT1 gene encodes the KNa channel subunit KCNT1, called Slack (sequence such as a
calcium-activated potassium channel). Mutations in KCNT1 gene have been found in different
epilepsy syndromes (EIEE 14): autosomal dominant nocturnal frontal lobe epilepsy (ADN-
FLE), epilepsy of infancy with migrating focal seizures (EIMFS), and other types of EOEEs,
including OS [62]. Patients displaying KCNT1 mutations have a very high occurrence of severe
mental and intellectual disability.
3.2.3. SCN2A (MIM 182390)
The three isoforms of the brain sodium channel alpha subunit are encoded by three distinct
sodium channel, voltage-gated genes (SCN1A, SCN2A, and SCN3A) that share a common
ancestral origin [63].
De novo mutations in SCN2A are increasingly recognized as a cause of an early-onset seizure
and developmental delay. The clinical spectrum named EIEE11 (MIM 613721) includes OS and
benign familial infantile seizures-3 (BFIS3) [64]. While inherited SCN2A mutations have been
identified in multiple mild epilepsy cases, by contrast in cases with EIEE and severe or
profound developmental delay, the majority of mutations were de novo missense variants,
similarly to the abovementioned findings for KCNQ2 [45, 65].
3.2.4. STXBP1 (MIM 602926)
STXBP1 (mapping to 9q34.1) encodes the n-Sec1 (neural-specific, syntaxin-binding protein),
which participates in the constitutive secretory pathway between the Golgi apparatus and the
plasma membrane, and implicated in vesicle trafficking and NT release [66]. The mutation in
STXBP1 (named EIEE4, MIM 612164) shows a relatively similar phenotype to OS but with
frequent evolution to West syndrome [67] and cerebral hypomyelination in MRI brain imaging.
Mutations in STXBP1 are not limited to patients with Ohtahara or West syndrome, but are also
present in about 10% of patients with an EOEE without a specific recognized epilepsy
syndrome [68].
A de novo heterozygous missense mutation in the STXBP1 gene was found for the severe
phenotype of early infantile epileptic encephalopathy with suppression burst (EIEE4) [69, 70].
By contrast, a de novo truncating mutation in STXBP1 was identified in nonsyndromic intel-
lectual disability (NSID) with/without history of epilepsy [71, 72].
3.2.5. GNAO1 (139311)
The GNAO1 gene encodes an alpha subunit (Go, alpha subunit) of the heterotrimeric guanine
nucleotide-binding proteins (G proteins), a large family of signal-transducing molecules. Go-
alpha has been implicated in ion channel regulation. Most of the reported cases present EIEE17
(OMIM 615473), characterized by OS with intractable tonic seizures in the first weeks of life
associated with BS pattern on EEG, involuntary movements, and progressive cerebral atrophy.
Delayed myelination and thin corpus callosum were common features in brain images [73].
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A novel heterozygous missense pathogenic GNAO1 variant is report in an EIEE presented at
birth with twitching movements and convulsions, with nonspecific electro-clinical signs, and
no radiological abnormalities [74]. Other reports demonstrated that GNAO1 variants can cause
involuntary movements and severe developmental delay with/without seizures, suggesting
that GNAO1 variants can cause various neurological phenotypes [75].
3.3. Genetic mutations in EME
On a genetic point of view, several genes have been associated with EME.
3.3.1. SLC25A22 gene
As referred to above, the SLC25A22 gene is most often associated with EME (or EIEE 3) and
encodes mitochondrial carriers that transport a variety of metabolites across the inner mito-
chondrial membrane (it is one of the two mitochondrial glutamate/H+ symporters), with strong
expression in the developing brain. Mutated SLC25A22 expression in areas of the brain
decreased glutamate transport activity and contributed to the genesis and control of myoclonic
seizures [76]. Malignant migrating partial seizures in infancy (MMPSI, or EIEE14, OMIM
614959) that may occur as a result of heterozygous mutation in the KCNT1 gene (608167) on
chromosome 9q34 can also be caused by a SLC25A22 gene mutation, expanded the phenotypic
spectrum associated with this gene [77].
3.3.2. PIGA
Phosphatidylinositol glycan class A (PIGA, OMIM 311770) is involved in the first step of
glycosylphosphatidylinositol (GPI) biosynthesis, a glycolipid that attaches dozens of different
proteins to the cell surface. Many proteins, including CD55 and CD59, are anchored to the cell
by GPI. The loss of CD55 and CD59 on erythrocytes causes complement-mediated lysis in
paroxysmal nocturnal hemoglobinuria (PNH).
Multiple congenital anomalies-hypotonia-seizures syndrome-2 (MCAHS2, or EIEE20, OMIM
300868) is an X-linked recessive neurodevelopmental disorder characterized by neonatal
hypotonia, myoclonic seizures, dysmorphic features, and variable congenital anomalies
involving the central nervous, cardiac, and urinary systems. EEG, in the most severe cases,
showed hypsarrhythmia or BS pattern. Some affected individuals die in infancy [78].
3.3.3. SIK1
SIK1 (OMIM 605705) is a member of the AMP kinase subfamily with several roles in the CNS
and is involved in the regulation of corticotropin-releasing hormone in the hypothalamus. SIK1
abundance and activity are also increased by stimulation with ACTH (adrenocorticotrophic
hormone), which is a first-line treatment for ISS [79].
The mutations in SIK1 gene have been associated with a spectrum of developmental epi-
lepsies [80], mainly EME (EIEE30, 616341), and also with OS and ISS. Brain was either nor-
mal, mild hypoplasia of the frontal lobes. Interestingly, one of the patients described in
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this work that developed intermittent myoclonic jerking movements did not respond to
anticonvulsants. Their EEG on day 14 of life showed BS pattern, and at 8 months of age
the EEG had not improved, with continued BS associated with both myoclonic and tonic
seizures. Brain MRI showed no structural malformations. In another OS patient with tonic
seizures, the brain exhibited “a simplification of the gyral pattern”, and asymmetric thin-
ning of the WM. This evidence also supports the idea that tonic seizures in OS are associ-
ated with structural and static brain damage, while the EME requires a good cerebral
cortical development.
3.3.4. Neuregulin-1 receptor ErbB4
The neuregulins (NRGs) are cell-cell signaling proteins that are ligands for receptor tyrosine
kinases of the ErbB family. Recently, it has been known also that disruption in the neuregulin-1
receptor ErbB4 (family members of tyrosine kinase receptors, OMIM 600543) also contributes
to EME (OMIM 609304) [81] by impairing interneuron migration [82] and altering the number
of GABAergic interneurons in the postnatal cortex [83]. NRG1 is crucial for maintaining a
normal radial glial scaffold and signals allowing neuronal migration. It also induces the
expression of brain lipid-binding protein (BLBP), a well-known marker of radial glia [84].
NRGs also regulate the timing of astrogenesis in the developing brain [85], as well as in the
myelination of Schwann cells [86].
3.4. Genetic analysis for copy number variants (CNVs)
Advances in molecular genetic testing have greatly improved diagnostic rates in EIEE, with
an important role of array-comparative genomic hybridization (array-CGH) investigation in
this group of disorders. Array CGH can readily detect micro-chromosomal aberrations at a
much finer resolution than the 5-Mb limit of the conventional karyotype. There are over 200
disorders where epilepsy is or can be part of the clinical condition, but not the primary feature
(Online Mendelian Inheritance in Man, OMIM). Many of these can be associated with various
micro-chromosomal anomalies; therefore, the array CGH is more widely applied as a frontline
diagnostic tool, especially for children with syndromic epilepsy.
CNVs can be recurrent due to non-allelic homologous recombination (NAHR) in “hotspots”
regions of segmental duplication (SD) or low-copy repeats (LCRs). The most common of
the recurrent microdeletions associated with generalized epilepsy are typically seen at a
frequency close to 1% at 15q13.3, 16p13.11, and 15q11.2. These loci also confer susceptibili-
ty to ID, autism spectrum disorders (ASDs), and schizophrenia (for a review, see [87]).
Rare copy number variants—deletions and duplications—have recently been established
as important cause of epileptic encephalopathies. Pathogenic CNVs play an important role
in the genetic etiology of unknown cause EOEEs: 7.9% of affected individuals carried at
least one rare CNV [88], and in at least 3.4% [89] to 4.1% [88] of patients, CNVs were
clearly pathogenic.
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4. GABAergic neurons in the developing brain
To accomplish stability, neurons must maintain a homeostatic balance between adjustment
output (to meet new requirements) and preservation output within a satisfactory performance
range. This balancing act is performed through the combination of synaptic plasticity and
changes in intrinsic neuronal excitability. The neuronal components of brain circuitry are
generally considered to be “stable” across an animal’s life, excepting the growth and degen-
eration phases that happen during development, aging, or pathology. The periods of greatest
neuronal instability occur during the early ontogenesis and CNS development. The EEA
(glutamate and especially GABA acting like an excitatory) plays a fundamental role in the
developing brain. The hypothesis of a “homeostatic-like” regulation [90] (by NT and receptors)
of neuronal migration that controls final position, timing, and number of cells at destination
depends on the following:
– the type of migration: radial, tangential, or chain migration;
– the type of cells: principal glutamatergic neurons versus GABAergic interneurons; and
– the brain area: neocortex, cerebellum, rostral migratory stream.
4.1. Distinct modes of migration in the developing cortex
The newly specified neurons migrate long distances before they differentiate and form
synapses. Neuron migration routes in the developing mammalian brain are generally a long
and complex process, but it can be summarized in the following: (for a review, see [91, 92])
a. Radial-type migration: postmitotic neurons migrate away from the germinal ventricular
zone to their positions in the developing cortex, using two forms of radial movement:
somal translocation, which is adopted by the early-generated neurons, and glia-guided
locomotion, which is used predominantly by pyramidal cells.
b. Tangential-type migration: cortical interneurons migrate tangentially into the cortex and
then seek the ventricular zone before moving radially to take up their positions in the
cortical anlage.
4.2. Transient and permanent circuitry elements
In lower mammals, all hippocampal and almost all neocortical neurons are born in a specific
region named ganglionic eminence in the ventral (basal) part of the telencephalon. The
glutamatergic principal cells (i.e., projection neurons) migrate from the proliferative layer to
their target region following a radial orientation. Meanwhile, GABAergic interneurons via
long-distance tangential migration (parallel to pial surface) move from the ganglionic emi-
nence to their target layer in the cerebral cortex. A substantial body of evidence indicates that
in humans neocortical GABAergic interneurons of local cortical circuitry are likely to originate
in two different areas: 65% are born in the ventricular/subventricular zone of the dorsal
telencephalon, and 35% originate from the ganglionic eminences (proliferative zones of the
subpallium) [93].
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The subplate zone (SPZ) is a transient cytoarchitectonic compartment of the fetal telencephalic
wall, situated between the fetal white matter (WM) (i.e., intermediate zone) and the cortical
plate, and it is the crucial laminar compartment for the development of the human cerebral
cortex. The subplate contains numerous neurons of various morphological types and molec-
ular phenotypes, including differentiated projection (glutamatergic) neurons and local (GABA
and peptidergic) interneurons [94]. The developing human cortex goes through three major
early stages of functional development: (1) between 13 and 15 postconceptional weeks (PCW):
initial-transient fetal circuitry, centered at the SPZ, which is endogeneously (spontaneously)
driven; (2) 15 and 30 PCW: perinatal dual circuitry (coexistence of endogeneously driven
subplate-centered transient circuitry with developing cortical plate-centered permanent
circuitry) that slowly disappears toward the end of gestation and during the early postnatal
period; and (3) postnatally established permanent (externally driven) cortical circuitry,
centered at the cortical plate (i.e., developing cortical layers I–VI). While the SPZ disappears
during the perinatal and early postnatal period, numerous subplate neurons survive and
remain embedded in the superficial (gyral) WM of adolescent and adult brain as the so-called
interstitial neurons [95]. There is also a prolonged coexistence of transient and permanent
circuitry elements in the developing cerebral cortex. Therefore, the neuronal elements in
transient fetal zones form a developmental potential for plasticity after perinatal cerebral
lesions [96].
The subpallium also generates oligodendrocytes (OLs) that migrate in a similarly tangential
path to the cortex. These are the cells that give rise to myelin, a major component of WM, and
play an important role in assuring fast neuronal signaling in the CNS [97]. The proliferation
and differentiation of developing oligodendroglial cells and their myelination of axons are
partly controlled by NT (glutamate, GABA, glycine, etc.) (for a review, see [98]). Numerous
studies refer connections among this OLs and the GABAergic system [99, 100]. The growth of
the axonal pathways in preterm newborn explains their vulnerability and plasticity, while
conversely in neonates the vulnerability is related to the intracortical circuitry. In addition to
OLs loss, axonal disruption, and excess apoptosis, a significant loss of telencephalon GABAer-
gic subplate neurons expression was found in neonatal brains with WM lesions, compared
with neonatal brains without WM lesions, which could contribute to the pathogenesis of
neurological deficits in children [101]. On the other hand, innate immunity mediated by
microglia plays a crucial role in initiating and propagating seizure-induced inflammatory
responses, as long-term epileptogenic effects of early-life seizure, such that seizure-induced
microglia activation primes the central immune response to overreact and to increase the
susceptibility to a second seizure later in life [102].
4.3. GABAergic interneurons
GABAergic neurons in cerebral cortex mostly correspond to local circuit neurons (interneur-
ons), which release GABA as their output, and are the major inhibitory cells of the mature CNS.
Despite including only 20–30% of the cerebral cortical neuronal population, these cells play an
essential part and mighty role in modulating the electrical activity in the synapse of the
excitatory pyramidal cells. In the epileptogenic neocortex, there is preferential loss of GA-
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BAergic neurons, namely “basket cells” (BCs) and chandelier cells (ChCs) (for a review, see
[103, 104]).
The interest in developing human cortex and GABAergic neurons has increased in the past
decade. GABAergic interneurons develop early in the cortical anlage during embryonic
development, whereas glutamatergic activity arises later. Although interneurons are present
in all regions of the mature telencephalon, many studies have shown that during embryogen-
esis these cells are generated in specific compartments of the subcortical telencephalon and
migrate across WM to reach their final destinations in the mature brain. Studies of histological
sections of progressively more developed embryonic brains revealed that GABAergic cells
were firstly present in the preplate, subventricular, and ventricular proliferative zones,
migrated later to the subplate, marginal zone, and intermediate zones and finally reached the
cortical plate (for a review, see [93, 105]).
Despite progress toward understanding the genetic determinants that specify the fate of neural
progenitors, much remains unknown about the complex molecular machinery that directs the
migration of immature neurons to specific regions of the cerebrum. Interestingly, in addition
to its function in synaptic transmission, NTs have been shown to promote several develop-
mental processes that contribute to the creation and maintenance of the CNS. In this regard, a
growing body of literature has highlighted a role for NT through the activation of its receptors
in the regulation of cell migration in the telencephalon during development and in adulthood
[106, 107]. Thus, it seems that the activation of GABAAR regulates neuronal proliferation,
migration, and differentiation of GABAergic interneurons in the developing cerebral cortex
[108]. Most interestingly, GABAergic interneuron dysfunction may contribute to a subset of
genetic developmental epilepsies [104]. It is also worth noting that, in experimental animals,
it has been shown that status epilepticus altered neurogenesis and decreased the number of
GABAergic neurons in the septal dentate gyrus at the early phase of epileptogenesis. This
could modify the connectivity between these cells and disturb the maturation of the GABAer-
gic neurotransmission in the immature brain [109].
Lévesque et al. [110] described the interneurons spark seizure-like activity in the cortex in an
in vitro model of epileptiform synchronization:
– Interneurons (66.7%) are more likely to fire in association with interictal discharges than
principal cells (35.3%).
– The pre-ictal period is characterized by increased interneuron firing that reaches its peak
at ictal onset, while the activity of principal cells does not change.
– The tonic phase of the ictal discharges is associated with high firing from interneurons
that fire in a phase-locking relationship with low-voltage fast (LVF) oscillations.
– Interneurons continue to generate action potentials in association with the interictal
discharges occurring during blockade of ionotropic glutamatergic transmission.
Their results illustrate the major role of interneurons in interictal discharge generation and in
the transition to ictal activity.
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5. Excitotoxicity in developing brain
Amino acids are among the most abundant NTs in the CNS, and most neurons use GABA and
glutamate, both primary regulators of the excitability of most neurons in the brain (glutamate
is an excitatory NT, while GABA is an inhibitory NT in the adult mammalian brain), and are
therefore involved in important physiological processes and in pathophysiologic events.
Receptor families of EAA are overexpressed in the immature brain. Due to the abundance of
EAA receptors in early ontogenesis and age-dependent changes in intrinsic neuronal excita-
bility, an excitotoxic hypothesis as the source of neonatal seizures seems plausible, even though
some observations do not support this theory [8]. Many reports reviewed here aimed to
demonstrate that both NTs (GABA and glutamate) modulate neuronal migration and brain
maturation in humans by early paracrine actions, and cytoskeletal dynamic changes are
regulated by intracellular calcium. Thus, there is evidence that the activation of specific GABA
and glutamate receptors is instrumental in cell migration by promoting motility and acting as
an acceleratory or stop signal. Therefore, the modification of glutamate and GABAergic
systems, among other mechanisms, can trigger disorders in cortical migration of neurons, the
most common CNS developmental alteration observed in human patients and a significant
cause of seizures [9].
5.1. The amino acid glutamate
Glutamate is the major excitatory NT in the CNS, released from both neurons and glial cells.
During neurotransmission, glutamate is released from presynaptic neurons by means of
depolarization of the presynaptic neuronal end plate and then diffuses across the synaptic cleft
to activate postsynaptic glutamatergic receptors.
The mammalian genome contains five glutamate transporter genes—“solute carrier family”
—(EAAT1, slc1a3; EAAT2, slc1a2; EAAT3, slc1a1; EAAT4, slc1a6; EAAT5, slc1a7). The most
important and most abundant transporters for the removal of transmitter glutamate in the
brain are EAAT2 (GLT-1) and EAAT1 (GLAST). These transporters keep the extracellular level
excitatory amino acids low and provide amino acids for metabolic purposes (for a review, see
[111]).
Glutamate is one of the NTs with the most receptors; therefore, its classification is complex.
There are two known groups of glutamate receptors: ionotropic (iGluRs, ligand-gated ion
channels) and metabotropic (G-protein-coupled) receptors. IGluRs are further divided into the
following subgroups with respect to their pharmacological properties: GluN (the N-methyl-
D-aspartic acid), GluA (AMPA, the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic
acid), GluK (kainate), and GluD (δ) receptors [112]. NMDA receptors are named “slow” (slow
transmission, synaptic currents are typically very slow) and non-NMDAs “fast” (fast trans-
mission, synaptic currents are typically very fast) [113].
Metabotropic glutamate (mGlu) receptors are further subdivided into three groups of eight
subtypes: group I with components mGlu1 and mGlu5 (coupled to Gq/G11), group II consist-
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ing of mGlu2 and mGlu3; and group III composed of mGlu4, mGlu6, mGlu7, and mGlu8
(members of both latter groups are coupled to Gi/Go) [114].
Glutamate receptors are regulated in both neuronal and glial cells within the developing brain.
Rapid synaptic excitation in the CNS is mediated primarily by the activation of postsynaptic
ionotropic (AMPA and NMDA) glutamate receptors. Both of these receptors play different,
well-defined roles in excitation: AMPA receptors (AMPARs) are considered to be the primary
mediators of fast neurotransmission under resting conditions, whereas NMDA receptors,
based on their unique properties, detect the coincidence of glutamate release and postsynaptic
depolarization and are involved in the induction of long-term synaptic changes [115, 116].
Several studies indicate that glutamate receptor-mediated excitotoxicity is a key player in
neuronal and glial cell death and that its involvement in the developing brain is more critical
than in the adult brain [117, 118]. Other studies have shown a dual effect of glutamate on
GABAergic interneuron survival during cerebral cortex development, expressed as either
excitotoxicity lesions or antiapoptotic effects depending on the cortical layers. In layer VI,
NMDA led to excitotoxicity, sustained calcium mobilization and necrosis; conversely, in the
immature layers II–IV, NMDA decreased apoptosis and induced transient calcium mobiliza-
tion [119].
5.1.1. NMDA receptors
The NMDA receptor is an essential executive and integrative element of the glutamatergic
system and crucial for proper functioning of neuronal circuits. NMDA receptors have received
a great deal of attention over the last few decades, due to their key role in neuronal excitotox-
icity (their hypofunction or overactivation can result in neuronal disturbances and neurotox-
icity) and their involvement in many types of neural plasticity (for a review, see [120, 121]).
The NMDA receptor subunits in the developing brain create populations of receptors that flux
more calcium, open more easily, and block less frequently than mature forms, allowing these
receptors to fulfill their special role in development. However, this makes the immature brain
more susceptible to excitotoxic injury if energy levels are compromised. For instance, neuro-
toxicity mediated by NMDA is more enhanced in the neonatal brain than in the adult brain.
Therefore, development-dependent changes in the expression of NMDA receptor subunits and
their composition are, at least, partially responsible for the fact that immature brains are far
more excitable and epileptogenic than the adult brain. Nevertheless, the important role that
NMDA receptors play in activity-dependent neuronal plasticity during development contra-
indicates treatments that block NMDA receptors at specific neurodevelopmental stages due
to their potential adverse effects on brain development [122].
5.1.2. AMPA receptors
AMPA receptors are Na+ and K+ (in some cases Ca2+) permeable ion channels constituted by
four subunits (GluA1-GluA4), playing the major determinants of the rapid component of
excitatory synaptic currents in the brain. They exhibit fast activation and deactivation kinetics
aside from rapid desensitization. The receptor subunits interact with transmembrane AMPA
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regulatory proteins (TARPs), exerting its influence on the synthesis, trafficking and localization
of AMPA receptors at the cell surface, aside from their functional properties such as open
probability, channel conductance, activation, deactivation, and desensitization [121].
In the developing brain, early alterations of the AMPA receptors (AMPARs) play a significant
role in epileptogenesis, seizure susceptibility, and seizure-induced neuronal injury, and
mediate synaptic potentiation induced by neonatal seizures [123]. Changes in AMPA receptor
number are of great significance for CNS function, for instance, in shaping mechanisms
underlying synaptic plasticity in cognitive aging [124]. Several studies have thrown light on
the role of AMPA receptor maturation in perinatal seizures and brain injury. In immature
subjects, AMPA receptors are relatively overexpressed in WM OLs, while after maturation
those receptors predominate in neurons of cortex and hippocampus. Besides, in rodent models,
it has been observed that hypoxia/ischemia causes neuronal damage at postnatal day 7 and
seizures at postnatal days 10–12, but not at younger or older ages. These effects were found to
be reversible by the administration of an AMPA receptor antagonist [125].
5.2. The amino acid GABA
GABA is a major NT expressed from the embryonic phase and throughout life. GABA is a
versatile molecule with multiple functions during neocortical development and plays an
important role in the developing brain even prior to synaptogenesis: stem cell proliferation,
migration, synaptogenesis, and circuit formation. These diverse roles of GABA seem to depend
both on cell-intrinsic properties (particularly high intracellular Cl− gradient in immature
neurons) and on extrinsic factors [126]. By changing the excitatory/inhibitory balance, GA-
BAergic plasticity can regulate excitability, neural circuit function, and contribute to learning
and memory [127]. GABA exerts depolarizing effects mostly contributing to the expression of
spontaneous activities that are instructive for the construction of neural networks but GABA
also acts as a potent trophic factor (for a review of metabolism and transport, see [128, 129]).
The mammalian genome contains four genes encoding GABA transporters—“solute carrier
family”—(GAT1, slc6a1; GAT2, slc6a13; GAT3, slc6a11; and the Betain/GABA transporter type
1 (BGT-1), slc6a12). GABA transporter types 1 and 3 (GAT-1 and GAT-3, respectively) are the
two main subtypes of GATs responsible for the regulation of extracellular GABA levels in the
central nervous system [111, 130]. GABA is actively taken up by neuron and astrocyte carrier
proteins and broken down into succinic acid semialdehyde by glutamic acid decarboxylase
(GAD) or repackaged into a vesicle that is released again at the next synaptic transmission
[131].
There are two main types of GABA receptors: the ionotropic GABAsubtype A receptor and
the metabotropic GABAsubtype B receptor [93]. The GABA receptor type A (GABAA receptor)
is a ligand-gated chloride channel that mediates major inhibitory functions in the adult CNS.
GABAA receptors function mainly as pentamers containing α, β, and either γ or δ subunits. At
an early developmental stage, GABA, acting at GABAA receptors, produces a rapid synaptic
excitatory response and is implicated in most processes of neurogenesis, including neuronal
migration, proliferation, differentiation, and preliminary circuit building. In the mature CNS,
GABA acts in an inhibitory manner, a switch mediated by chloride/cation transporter expres-
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sion. In contrast to the ionotropic GABAA receptors, GABAB receptors are responsible for the
latter and slower component of inhibitory transmission [132]. The composition of GABAA
receptors is different in newborns, with less α1 and more α2/3 subunits, rendering them less
responsive to benzodiazepines [133].
In the adult NS, due to low intracellular levels of neuronal chloride [Cl−] gradients, GABA
inhibits most neurons by the activation of GABA subtype A receptor channel chloride currents
(GABAARs), causing Cl− influx, membrane hyperpolarization, and inhibition. During devel-
opment, GABAergic neurotransmission undergoes a switch from excitatory to inhibitory due
to a reversal of [Cl−] gradients [134]. In immature neurons, high levels of expression and robust
activity of the chloride-importing Na-K-2Cl cotransporter NKCC1 cause the accumulation of
intracellular [Cl−] and, therefore, a depolarized Cl− equilibrium potential, responsible for an
excitatory effect in the developing brain; besides the Cl− exporting activity of KCC2 is lower
than in mature neurons, and in the context of NKCC1 expression, neuronal [Cl−] is higher
and GABAA reversal potential (EGABA) is more depolarized, such that the binding of GABA
to ligand-gated GABAA receptor-associated Cl− channels triggers Cl− efflux and depolarizing
excitation. This results in the outward flux of [Cl−] through GABAA channels, the opposite
direction compared with mature neurons. In adults, NKCC1 expression decreases and the
expression of the genetically related chloride-extruding K-Cl cotransporter KCC2 increases,
which turns GABAA receptor activation inhibitory because Cl− flows into the cell (for a review,
see [135]).
6. GABAergic system in early-life epilepsies
The incidence of seizures classified as reactive, symptomatic, or idiopathic is particularly high
in the early ages of life. The most common reactive seizures in early life are febrile convulsions,
although they must be differentiated from symptomatic seizures precipitated by fever.
Symptomatic seizures are often associated with different levels of CNS insults, including HIE,
metabolic storage diseases gray matter, and brain congenital malformations. In the neuronal
migration disorders and idiopathic seizures, increasingly a genetic defect can be identified
(e.g., LIS1 mutations for lissencephaly). In all these instances, the GABAergic system has been
proposed as a key player in “age-dependent vulnerability to seizures” [136, 137].
During seizures, the release of GABA occurs, and this outward flow of Cl− in neonatal neurons
is excitatory. The immaturity of GABAergic inhibitory systems has been implicated in the
heightened susceptibility of neonates to seizures in early-life epilepsies, and contributes to a
greater seizure propensity and poor electroencephalographic response to GABAergic anti-
convulsants such as phenobarbital (PB) and benzodiazepine [133]. This is thought to be due
to shunting inhibition or inhibition via excitatory effects upon inhibitory interneurons [138].
During seizures, the excessive GABAergic stimulation of the substantia nigra reticulata that is
believed to occur has been reported to be proconvulsant in neonatal animals while it would
be anticonvulsant at older ages [139]. This developmental switch seems to occur earlier in
female rats [140]. But in addition to GABA synapses, also the intact glutamatergic transmission
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has been linked to the appearance of a BS pattern [141]. Therefore, certain neocortical cell types
may act as EEG burst-suppression pacemakers, in particular the “fast-rhythmic-bursting”
neurons described in neocortex [142].
Gene symbol Titles Locus OMIM EIEE
Genes impair interneuron migration
ARX Aristaless-related homeobox, X-linked Xp21.3 300382 EIEE 1/LISX2
HER4/ERBB4 Tyrosine kinase–type cell surface receptor HER4
(Neuregulin-1receptor ErbB4)
2q34 600543 EIEE 3 (EME)
Genes encoding ion channels
SCN1A Sodium channel, neuronal type 1a subunit; 2q24.3 182389 EIEE 6 or Dravet Synd.
GEFSP2/FEB3A/MHP3
SCN2A Sodium channel neuronal type 2a subunit 2q24.3 182390 EIEE 11/BFIS3
SCN8A Sodium channel neuronal type 8a subunit 12q13 600702 EIEE 13
KCNA2 Potassium channel, voltage-gated, shaker-related subfamily,
member 2
1p13.3 176262 EIEE 32
KCNQ2 Potassium channel, voltage-gated, KQT-like subfamily,
member 2
20q13.3 602235 EIEE 7/BFNS1
KCNB1 Potassium channel, voltage-gated, Shab-related subfamily,
member 1
20q13.13600397 EIEE 26
KCNT1 Potassium channel, subfamily t, member 1 9q34.3 608167 EIEE 14
CACNA2D2 Calcium channel, voltage-dependent, alpha 2/delta subunit 2 3p21.31 607082 VUS
HCN1 Hyperpolarization-activated cyclic nucleotide–gated
potassium channel 1
5p12 602780 EIEE 24
Genes encoding regulators of synaptic vesicles release
DNM1 Dynamin-1 9q34.11 602377 EIEE 31
NECAP1 Necap endocytosis–associated protein 1 12p13.31611623 EIEE 21
TBC1D24 Tbc1 domain family, member 24 16p13.3 613577 EIEE 16
STXBP1 Syntaxin-binding protein 1 9q34.1 602926 EIEE 4
Genes encoding regulators of intracellular/intercellular signal transduction
DOCK7 Dedicator of cytokinesis 7 1p31.1 615730 EIEE 23
GNAO1 Guanine nucleotide–binding protein, alpha-activating activity
polypeptide 1
16q13 139311 EIEE 17
ARHGEF9 Rho guanine nucleotide exchange factor 9 Xq11.1 300429 EIEE 8/hyperekplexia
ST3Gal III St3 beta-galactoside alpha-2,3-sialyltransferase 3 1p34.1 606494 EIEE 15
GABAergic Interneurons in Severe Early Epileptic Encephalopathy with a Suppression-Burst Pattern: A Continuum...
http://dx.doi.org/10.5772/64458
69
Gene symbol Titles Locus OMIM EIEE
WWOX Ww domain-containing oxidoreductase 16q23 605131 EIEE 28
SPTAN1 Spectrin, alpha, nonerythrocytic 1 9q34.11 182810 EIEE 5
PCDH19 Protocadherin 19 Xq22.1 300460 EIEE 9
PLCB1 Phospholipase c, beta-1 20p12.3 607120 EIEE 12
PIGA Phosphatidylinositol glycan, class A Xp22.2 311770 EIEE 20
AARS Alanyl-tRNA synthetase 16q22.1 601065 EIEE 29
SIK1 Salt-inducible kinase 1 21q22.3 605705 EIEE 30
ALG13 Asparagine-linked glycosylation 13 Xq23 300776 EIEE 36
Genes encoding neurotransmitters membrane receptors
GRIN 2A Glutamate receptor, ionotropic, N-methyl-D-aspartate,
subunit 2ª
16p13.2 138253 FESD
GRIN2 B Glutamate receptor, ionotropic, N-methyl-D-aspartate,
subunit 2b
12p13.1 138252 EIEE 27
GABRA 1 Gamma-aminobutyric acid receptor, alpha-1 5q34 137160 EIEE 19
Genes encoding intracellular transporters
SLC12A5 Solute carrier family 12 (potassium/chloride transporter),
member 5
20q13.12606726 EIEE 34
SLC13A5 Solute carrier family 13 (sodium-dependent citrate transporter 17p13.1 137160 EIEE 25
SLC25A22 Solute carrier family 25 (mitochondrial carrier, glutamate)
member 22
11p15.5 609302 EIEE 3 (EME)
SLC35A2 Solute carrier family 35 (UDP-galactose transporter), member
2
Xp11.23 314375 EIEE 22
EEF1A2 Eukaryotic translation elongation factor 1, alpha-2 20q13.33602959 EIEE 33
Genes encoding enzymes
SZT2 Seizure threshold 2 1p34.2 615463 EIEE 18
CDKL5 Cyclin-dependent kinase–like 5 Xp22.13 300203 EIEE 2
PNKP Polynucleotide kinase 3-prime phosphatase 19q13.4 605610 EIEE 10
ITPA Inosine triphosphate pyrophosphohydrolase 20p13 147520 EIEE 35
EIEE: early infantile epileptic encephalopathy. LISX2: lissencephaly, X-linked 2. EME: early myoclonic encephalopathy.
GEFSP2: epilepsy, generalized, febrile plus, type 2. FEB3A: febrile seizures, familial, 3A. MHP3: migraine, familial
hemiplegic, 3. BFIS3: benign familial infantile seizures-3. BFNS1: benign familial neonatal seizures. VUS: variant of
uncertain significance because its contribution to EIEE has not been confirmed. FESD: focal epilepsy and speech
disorder.
Table 3. Genes of early-onset epileptic encephalopathies.
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Mutations or genetic variations of the genes encoding the α1, α6, β2, β3, γ2, or δ subunits
(GABRA1, GABRA6, GABRB2, GABRB3, GABRG2, and GABRD, respectively) of the GABAA
receptor have been associated with the pathomechanisms of human epilepsy and genetic
epilepsy syndromes, both with and without febrile seizures syndromes, including pure febrile
seizures (FSs), generalized epilepsy with febrile seizures plus (GEFS+), Dravet’s syndrome (DS,
also known as severe myoclonic epilepsy in infancy, SMEI), childhood absence epilepsy (CAE),
and juvenile myoclonic epilepsy (JME). Related genotypic and phenotypic spectra of muta-
tions of GABAA receptor are changeful, thus, mutations of GABRA1 (137160) in 5q34 were
associated with EIEE19 or DS. Recently, mutations of GABRA1, GABRB2, and GABRB3 were
associated with ISS and Lennox-Gastaut syndrome, and also GABRB3-related EOEE [143].
These mutations that compromise hyperpolarization through GABAA receptors are found in
both translated and untranslated gene regions. Interestingly, most of the insufficiencies are not
caused by receptor-gating abnormalities, but by multiple mechanisms, including (I) endo-
plasmic reticulum (ER)-associated degradation; (II) reducing subunit mRNA transcription or
stability, impairing subunit folding, stability, or oligomerization; (III) intracellular-trafficking
defects; and (IV) ER stress [144, 145].
While ion channel genes were considered for a long time as the only major group of genes
involved in genetic epilepsies, at present, an increasing number of non-ion-channel genes and
new pathways have been identified and it is difficult to find a common mechanism to explain
EOEE. In 2015, Mario Mastrangelo [43] summarized clinical presentations, genotype-pheno-
type relationships, and genes involved in the pathogenesis of EOEE comprising genes
encoding ion channels, regulators of synaptic vesicles release, regulators of intracellular/
intercellular signal transduction, NT, membrane receptors, intracellular transporters, and
enzymes (see Table 3).
The study of epilepsy due to single gene defects has helped to clarify certain seizure mecha-
nisms. The role of ARX mutations is well defined on downstream targets of this interneuron-
expressed transcription factor as well as their effects on cell migration and maturation of
GABAergic interneurons, which can help to explain the phenotype of ISS and electrographic
seizures [146]. During the early stages of development, ARX is expressed in a significant
proportion of neurons in the cortex, striatum, ganglionic eminences, and the spinal cord. In
the adult, the expression of ARX is still present but restricted to regions that are known to be
rich in GABAergic neurons, such as the amygdala and olfactory bulb [47]. SCN1A mutations
also implicate a predominant role for GABA interneurons due to disturbed GABAergic
function [147].
A variety of the named “epilepsy-age-dependent epileptic encephalopathies” is considered to
share a common pathological mechanism connected with the structural and functional
disturbance of interneurons, and therefore they have been designated with a new term
“interneuronopathies” [55, 148, 149, 150]. However, not only interneurons but also pyramidal
neurons could be at the origin of these encephalopathies. Therefore, those genes that disrupt
the glutamate metabolism via mitochondrial respiratory chain damage (i.e., mitochondrial
glutamate carrier SLC25A22) should also be considered as an important cause of the neonatal
epileptic encephalopathy (EME, EIEE3) [151].
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Another example of a gene that presents mutations related to EIEE23 is DOCK7 (Dedicator of
cytokinesis 7, locus 1p31.3). Overexpression of human DOCK7 in transfected embryonic rat
hippocampal neurons induced the formation of multiple axons, whereas knockdown of Dock7
inhibited axon formation. DOCK7 is an important regulator of microtubule assembly both in
the context of neurogenesis and in the establishment of neuronal polarity in newborn pyra-
midal neurons. It also promotes the development of nascent axons by activating Rac1 (a Rac
guanine nucleotide exchange factor). In addition, DOCK7 controls the development and the
morphological differentiation of GABAergic interneurons in the developing cortex. In human,
the loss of DOCK7 function causes a syndromic form of epileptic encephalopathy and cortical
blindness (EIEE23) by affecting multiple neuronal processes, with different types of seizures,
including tonic seizures, infantile spasms myoclonus, partial complex seizures with rotation
of the head, drop attacks, and tonic seizures among other crises [152]. Thus, some genes may
be involved in several pathways of cortical development.
Quoting the words of Connie Wu [93], “the so called “GABA shift” is a fascinating change in
the effect of GABA from depolarizing action in the developing brain to hyperpolarizing action
in the adult brain”. The depolarizing action of the GABAergic system would be governed by
glutamate with an inhibitory effect on this early excitatory activity of the GABA in the early
neocortex [153], and by GABAB receptors-mediated inhibition of GABAA receptor calcium
elevations in the developing hypothalamus, providing a mechanism for excitatory-inhibitory
balance during development [154].
Additionally, the full maturation of the GABAergic system in humans occurs after the neonatal
period. In the human cerebral cortex and WM, there is evidence that an important part of the
development of the GABAergic system takes place during the latter half of gestation and into
the first few years of infancy [155]. In point of fact, it is possible that the human GABAergic
system does not completely mature until adolescence [156]. The interruption of any aspect of
this sequence of events during development, due to either an environmental insult or genetic
mutations, could have devastating consequences on normal brain function [157], and may
interfere neuronal morphology, differentiation, and connectivity, manifesting as cognitive or
neurodevelopmental deficits. In the same vein, further dysregulation of inhibitory GABA
systems has been shown to play a major role in facilitating seizures, particularly marked in the
early neonatal ages [158].
One hypothesis that has been presented is that the normal variability in the number of
interneurons could explain the propensity of some individuals to develop epilepsy more than
others as a result of an injury or any other trigger that could lead to neuron loss. Particularly,
if chandelier cells (which are considered to be the most powerful cortical GABAergic inhibitory
interneuron) were affected, it would have serious consequences for the inhibitory control of
the pyramidal cells [159]. Recent data have shown that early postnatal transplantation of
interneuronal precursor cells increased GABAergic inhibition in the host brain and dramati-
cally suppressed seizure activity in epileptic mice [160]. These data create future expectations
for “the Promise of an Interneuron-based Cell Therapy for patients with intractable forms of
epilepsy” [161].
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7. Antiepileptic drugs (AEDs) in EIEE
As we mentioned previously, epilepsy in children represents a symptom of complex brain
diseases, presenting with a variety of syndromes, with many treatment options and disparing
results. The prognosis is generally good, with a large proportion responding well to the first
treatment given. But a substantial share (particularly children with epileptogenic encephalo‐
pathies), however, will not respond well to AEDs, despite aggressive and often off‐label use
of a variety of drugs. For these patients, the clinical goal is to find an optimal balance between
the benefits and side effects of a particular medication.
Before 1993, the management of epilepsy was limited to six major AEDs consisting of pheno‐
barbital, primidone, phenytoin, valproate, carbamazepine, and ethosuximide (ESM). These
were referred to as the “first‐generation AEDs” or traditional AEDs. Since the 1990s new drugs
were introduced and called “second‐generation” antiepileptic drugs, including felbamate,
gabapentin (GBP), lamotrigine, topiramate, tiagabine (TGB), levetiracetam (LEV), oxcarbaze‐
pine, zonisamide, vigabatrin (VGB), and pregabalin [162]. Newly published evidence‐based
treatment guidelines have helped physicians to choose the most effective AED in pediatric
epilepsy, although data do not always fully support new antiepileptic drugs due to lack of
well‐designed, randomized controlled trials [163].
At present, there are about 20 novel antiepileptic drugs, categorized as “third generation”.
Some of these drugs are derived from others that can be found in today’s market place. Among
the most representative include brivaracetam and seletracetam (analogs of levetiracetam),
pregabalin, ganaxolone (GNX) (belong to neurosteroids), carisbamate and fluorofelbamate
(analog of felbamate), rufinamide, safinamide (inhibit the release of glutamate), lacosamide,
eslicarbazepine (analog of the antiepileptic drug oxcarbazepine), and talampanel (glutamate
antagonist). Some of these drugs are recommended only in adults, but it is expected that they
would also be included for therapy in children in the future, as it happened with the second‐
generation AEDs (see Table 4).
The second‐generation AEDs have less effect on hepatic metabolism and cytochrome P450
induction, fewer drug interactions, and lower protein binding. Their off‐label use in pediatric
patients is fairly widespread and has given new options for the treatment of patients with
epileptic encephalopathy and refractory epilepsy, despite most of these agents not having US
Food and Drug Administration (FDA) indications for use [164, 165]. However, the newer AEDs
are not more efficacious than the older‐generation AEDs. In particular, there is no clinical
evidence to suggest that the newer agents should be considered as a first‐choice treatment in
any form of epilepsy in children [166].
The Task Force Report for the ILAE Commission of Pediatrics, in a recent report [167],
summarizes the recommendations for the management of infantile seizures. For focal seizures,
levetiracetam is effective (strong evidence); for generalized seizures, weak evidence supports
levetiracetam, valproate, lamotrigine, topiramate, and clobazam (CLB); for Dravet’s syndrome,
strong evidence supports that stiripentol is effective (in combination with valproate and
clobazam), whereas weak evidence supports that topiramate, zonisamide, valproate, bromide,
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and the ketogenic diet are possibly effective; and for Ohtahara syndrome, there is weak
evidence that most antiepileptic drugs are poorly effective.
Table 4. Mechanism of action of antiepileptic drugs (AEDs).
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Research on the molecular basis and pathways of some epilepsy syndromes has become
practical clinical task and has a clear value for both the patient and his family. It is now possible
for some cases to make therapeutic decisions made based on genetic findings of EIEE. This
capacity for precision therapy is expected to become more usual in the near future [168].
An extensive knowledge of the genes involved in EIEE may allow a more appropriate use of
AEDs based on their mechanism of action. The AEDs can also be grouped according to their
primary mechanism of action, although many of them have various actions and others have
unknown mechanisms of action. The main groups include (1) GABA enhancers and (2) non-
GABAergic antiepileptic drugs: sodium channel blockers, calcium current inhibitors, gluta-
mate blockers, neuronal potassium channel openers, carbonic anhydrase (CA) inhibitors, and
drugs with unknown mechanisms of action (see Table 4).
7.1. AEDs and GABAergic system
The current GABAergic antiepileptic drugs (especially GABA receptor agonists), while often
effective for adults, are not always capable of stopping seizures and preventing their sequelae
in neonates. The GABAergic drugs mainly include phenobarbital, benzodiazepines, tiagabine,
vigabatrin, gabapentin, valproate, and pregabalin.
7.1.1. GABA receptor agonists: drugs that enhance the actions of the neurotransmitter GABA
A number of antiepileptic drugs (AEDs) have agonistic effects on GABA subtype A (GABAA)
receptors. Currently, the first-line medical treatment for neonatal seizures is composed of drugs
that increase GABAARs, such as phenobarbital and benzodiazepines (clobazam, clonazepam);
another treatment strategy is the indirect manipulation of the GABAergic system, via the
modulation of neuronal Cl(−) gradients, by targeting the cation-Cl(−) cotransporters (NKCC1
and KCC2) or their regulatory signaling molecules [169].
• Phenobarbital (PB) increases GABAARs. PB has been the gold standard and remains the
preferred drug for the management of neonatal seizures for the treatment of seizures in
neonates [170]; however, PB controls seizures in less than half of newborns [171]. This
reduced efficacy of GABA-enhancing AEDs has been linked to neuronal chloride transport
in the developing brain. It is also intriguing to consider that recent insights regarding the
impact of maturational changes in neuronal chloride transporter expression on GABA
receptor function may provide strategies for adjunctive therapies of neonatal seizures, and
could improve the neuroprotective efficacy of PB in the neonate.
Specifically, blocking the neonatal neuronal chloride transporter with bumetanide (a specific
inhibitor of the NaC-KC- 2Cl- cotransporter NKCC1) can augment the inhibitory activity of
GABA agonists such as PB [172, 173]. Low concentrations of the diuretic bumetanide have been
shown to alter the ion gradient that underlies the excitatory effects of GABA. Blocking the
NKCC1 transporter with bumetanide prevents outward Cl- flux and causes a more negative
GABA equilibrium potential in immature neurons. While several studies have reported
anticonvulsant effects of bumetanide [174], others have found no significant anticonvulsant
effect. The alteration of Cl- transport by bumetanide reduces electrographic seizures, and the
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combination of bumetanide and PB is significantly more effective than PB alone on seizure
occurrence, frequency, and duration [172].
• Stiripentol (STP): STP enhances central GABA transmission through a barbiturate-like
effect, since it increases the duration of opening of GABA-A receptor channels, and also may
increase the GABA levels by interfering with its uptake and its metabolism. In 2007, the
European Medicines Agency granted STP a marketing authorization for Dravet´s syndrome
whose seizures are not adequately controlled with clobazam and valproate. The combina-
tion of STP with clobazam (CLB) and valproate seems promising for therapy of severe
myoclonic epilepsy in infancy (SMEN) with a responder rate of 54% [175], as well as to
suppress convulsive status epilepticus [176].
• Benzodiazepines: The benzodiazepines most often used for the treatment of epilepsy are
diazepam, midazolam, lorazepam, clonazepam, and clobazam. The first three drugs are
used primarily in protocols for emergency treatment of seizures and status epilepticus due
to their rapid onset of action, the availability of intravenous (IV) forms, and anticonvulsant
effects. Its use for long-term treatment is limited due to the development of tolerance.
Benzodiazepines are used in (phenobarbital) refractory cases of neonatal seizures [177].
– Clonazepam has higher affinity for the GABAA receptor site than diazepam and binds to
GABAA receptors that do not bind other benzodiazepines. Clonazepam is the drug of
choice for myoclonic seizures and subcortical myoclonus.
– Clobazam (CLB): In addition to its agonist action at the GABAA receptor, clobazam may
affect voltage-sensitive conductance of calcium ions and the function of sodium channels,
which makes CLB a potent anticonvulsant for partial epilepsy.
7.1.2. Uptake inhibitor (by blocking presynaptic GABA uptake)
Tiagabine (TGB) represents a new generation of AEDs. It is a derivative of nipecotic acid, with
a unique mechanism of action: uptake inhibitor, by blocking presynaptic GABA uptake. TGB
was approved for use by the FDA in 1997 as an adjunct agent for adults and children past 12
years of age with epilepsy, suffering from partial seizures, with and without secondary
generalization. Following a period of great enthusiasm for the use of TGB, it was put aside.
The FDA on 18 February 2005 issued a warning about the possible occurrence of nonconvulsive
as well as convulsive status epilepticus in a subset of nonepileptic and epileptic patients treated
with TGB [178], and should be under surveillance of frequency and severity of TGB overdoses
and reported to the American Association of Poison Control Centers (AAPCC).
There are very little data on TGB use in children, but this agent appears to be effective and
have a good tolerability profile and it still has its place in the treatment of drug-resistant
epilepsy.
7.1.3. GABA transaminase inhibitors (inhibition of the GABA-degrading enzyme)
• The Vigabatrin (VGB) has been widely used for the treatment of refractory epilepsies in
epileptic encephalopathies. The anti-seizure effect of VGB is a result of enhanced brain
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extracellular GABA levels by irreversible inhibition of the GABA-degrading enzyme GABA
aminotransferase (GABA-T) [179]. VGB inhibits GABA-T and elevates GABA in the
subthalamic nucleus (STN) [180].
ACTH, corticosteroids, and VGB are the first-line drugs for the treatment of ISS. However, the
detection of an irreversible visual field defect observed in as high as 30–50% of children treated
with VGB has contraindicated its use as first-line drug. Regarding West syndrome, there is
some evidence for the preference of hormonal treatments over VGB, except for children under
3 months. In children with tuberous sclerosis complex (TSC), VGB is the treatment of first
choice. Around 30% of patients who present with ISS respond well to treatment with VGB.
VGB should be considered as an early treatment option in early-onset epileptic encephalopa-
thies (EIEE and EME) [181]. Patients with mutation in STXBP1 gene could especially benefit
from treatment with VGB [182]. Interestingly, VGB can cause swelling and loss of myelin,
suggesting that excessive activation of GABAA receptors while oligodendrocytes are under-
going myelinization may be deleterious for that process [183].
7.1.4. GAD modulation
GAD modulation increases GABA turnover/synthesis of GABA.
• Gabapentin (GBP) was approved on January 1994 as an adjunctive treatment in patients 12
years or older with partial seizures, with or devoid of secondary generalization, which were
resistant to the traditional AEDs. GBP is an anticonvulsant GABA-mimetic and considered
as a structural analog of the inhibitory NT GABA. However, preliminary studies proposed
that GBP did not bind to either GABAA or GABAB receptors, nor was it transformed
metabolically into GABA. GBP prevents voltage-dependent sodium currents, and it is also
claimed to reduce presynaptic glutamate release and binding to postsynaptic calcium
channels and prevent central desensitization due to glutamate neurotransmission in the
dorsal horn of the spinal canal [184].
GBP has been used in both adults and children for numerous neurologic conditions, including
management of epilepsy, neuropathic pain (control of pain and irritability attributed to
neurologic impairment), refractory insomnia, and occasionally movement disorders (e.g.,
restless legs syndrome, dystonia, and nystagmus) [185]. GBP use for seizure has been limited
as a result of inconsistent efficacy and concern about seizure exacerbation (in particular,
aggravation of myoclonic seizures) [186]. GBP may significantly ameliorate dystonia severity
and improve activities of daily living and quality of life in children [187].
• Sodium valproate (VPA) acts through a combination of several mechanisms. Among the
mechanisms through which valproate exerts its anticonvulsant properties, an increase in
GABA turnover is included by significantly enhanced GABA inhibition in the cerebral
cortex, an action which is independent of its effect on spontaneous activity [188]. Thereby,
it potentiates GABAergic functions in some specific brain regions, such as substantia nigra,
thought to be involved in the control of seizure generation and propagation [189]. In
children, and especially in infants with epileptic encephalopathies, treatment with valproate
is preferred when proper diagnosis is not achieved [190].
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• Pregabalin: GBP and pregabalin are structurally related to the inhibitory neurotransmitter
GABA, and can modulate voltage-activated Ca2+ channels. The pharmacological activity of
pregabalin is similar but not identical to that of GBP. Pregabalin reduces excitatory proper-
ties by modulating voltage-activated Ca2+ and K+ channels. The actions of pregabalin may
involve both extracellular and intracellular drug target sites and modulation of a variety of
neuronal conductances, by direct interactions and through intracellular signaling involving
protein kinase A [191]. Pregabalin is remarkable for seizure control in children with
intractable epilepsy, and reduced more than 50% of seizure intensity in 40.2% of patients
[192], although there are no references to support the use of pregabalin in Ohtahara
syndrome.
7.2. Non-GABAergic antiepileptic drugs
7.2.1. Sodium channel blockers
With the increasing knowledge of the involvement of ion channels in the origin of epilepsy, a
greater number of publications that establish optimal treatment based on the genetic defect
have been appearing. This evidence may allow in the future to establish a "treatment on
demand." This is particularly important for genes encoding ion channels and sodium channel
blockers, such as:
– First generation: phenytoin (PHT), carbamazepine (CBZ);
– Second generation: oxcarbazepine (OXC), zonisamide (ZNS), lamotrigine (LTG);
– Third generation: eslicarbazepine, lacosemide.
Concerning Dravet’s syndrome (caused in 80% of cases by mutations in SCN1A), there is some
evidence showing that early aggressive therapy improves outcome, so genetic testing should
be considered early. The SCN1A protein appears to be mainly on inhibitory interneurons, and
treatment with sodium channel blockers such as lamotrigine and carbamazepine should be
avoided, whereas valproic acid, topiramate, clobazam, and stiripentol appear to be beneficial
[193, 194]. By contrast, in the epileptic encephalopathies associated with mutations in SCN2A
and SCN8A, their profile of drug responsiveness may be different since the proteins encoded
by these genes are localized in excitatory neurons. In fact, for SCN8A encephalopathy, sodium
channel blockers may be effective in some cases [195].
Regarding the Ohtahara syndrome caused by mutations in the KCNQ2 channel, recent
experience suggests that sodium channel blockers, carbamazepine, and phenytoin (40 and
33%, respectively, were seizure-free), are effective in this disorder. An effective treatment may
be important for reducing the neurodevelopmental impairment associated with this disorder
[60, 196].
Besides the known use of phenytoin for the treatment of neonatal seizures, other AEDs second
generation such as oxcarbazepine and zonisamide have been relatively well studied in
pediatric seizure patients, including their use as monotherapy. Both agents have demonstrated
good efficacy and tolerability for patients as young as 1 month old. Zonisamide is efficacious
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in pediatric epilepsy syndromes, including LGS, WS, OS [197], and for seizure control in
children with intractable epilepsy [192].
7.2.2. Calcium current inhibitors
• In addition to ethosuximide (ESM), other drugs such as topiramate (TPM) and LTG also act
as calcium currents inhibitors. Childhood absence epilepsy (CAE) is one of the most
common types of pediatric epilepsy. It is generally treated with ESM, VPA, or LTG. VPA-
LTG combination therapy has a good efficacy and fewer side effects than other treatments,
and it should thus be considered as a first-line therapy in absence of epilepsy [198]. ESM
next to clobazam and sulthiame is the most commonly used treatment in patients with
Landau-Kleffner syndrome (LKS), but it has no use in EIEE.
7.2.3. Glutamate blockers
7.2.3.1. NMDA antagonist
• Felbamate: Although felbamate has multiple mechanisms of action, it is thought to have its
most potent antiepileptic effects through the inhibition of the N-methyl-D-aspartate
receptor (NMDAR). Felbamate was approved in 1993 as a novel antiepileptic drug to be
used both as monotherapy and as an adjunctive therapy to treat partial seizures with and
without generalization in adults and as an adjunctive therapy for LGS. Despite its favorable
efficacy, there has been restricted approval of felbamate only for adjunctive therapy in
patients with LGS because of the occurrence of felbamate-related hepatotoxicity and
idiosyncratic aplastic anemia. Our current understanding of clinical data on the risk: benefit
of felbamate therapy supports its use as an important therapeutic option for some patients
with refractory epilepsy [199]. Early initiation of felbamate is recommended for children
with refractory epilepsy [200]. Felbamate monotherapy was able to achieve relevant
antiepileptic effects in a unique patient with neurofibromatosis type 1 (NF1) and tuberous
sclerosis complex (TSC) [201].
• Memantine: In a patient with a mutation in GRIN2A, encoding a glutamate NMDA receptor
subunit, memantine therapy (acting on the glutamatergic system by blocking NMDA
receptors) appeared effective [202]. This case exemplifies the potential for personalized
genomics and therapeutics to be utilized for early diagnosis and treatment of infantile-onset
neurological diseases.
7.2.3.2. AMPA/KAINATE antagonist
• Topiramate (TPM) exerts an antiepileptic effect via four mechanisms: (1) blockade of
voltage-dependent sodium channels, (2) GABAA agonist, (3) AMPA/kainate glutamate
receptor subtype, and (4) inhibition of carbonic anhydrase isoenyzmes type I and IV. In the
United States, topiramate currently is approved for (1) partial-onset and secondarily GTCs,
(2) primary GTCs, and (3) LGS. Currently, its use for the EOEE has not been established.
Although TPM is well studied in adults and older children, limited data exist for the
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application to neonates. The use of TPM in neonates has met with two significant challenges:
first, to date no intravenous formulation is commercially available, and second, there is
significant concern that TPM adversely affects language development [203]. TPM is a good
add-on drug in patients with epileptic encephalopathies such as LGS and myoclonic astatic
epilepsy. Regarding treatment options for ISS, TPM can be used when first-line drugs have
proven ineffective. Cessation of all spasms occurred in 32 [204] to 48% infants treated with
TPM [205]. In our experience (unpublished data), initial polytherapy with low dose of ACTH
and TPM was effective to suppress ISS in most patients, allowing to leave TPM—after
removal of ACTH—as AEDs of choice to prevent recurrence of the ISS. This combined
treatment has been endorsed by other authors [206, 207].
• Perampanel (PER): PER is a newer antiepileptic drug, first-in-class orally active, selective
noncompetitive AMPA receptor antagonist. In 2012, the European Union approved usage
for adjunctive therapy in partial-onset seizures (for patients age >12 years), with US approval
following in 2013 [208]. PER seems to be effective also in children and adolescents with
pharmaco-refractory epilepsies. Tolerability was acceptable [209]. But randomized control-
led trials in children are necessary to support its use.
7.2.4. Neuronal potassium channel openers
• Retigabine (RTG)/ezogabine: The new-generation drugs retigabine (RTG (international
nonproprietary name)) and ezogabine (EZG (US adopted name)) are the first neuronal
potassium (KV72-75) channel openers (act uniquely by enhancing the M-type potassium
current), and they are used as an adjunctive treatment for partial epilepsies in adult patients.
Mutations in KCNQ2 and KCNQ3, encoding the voltage-gated potassium channels KV 7.2
and KV 7.3, are known to cause BFNS1 and severe epileptic encephalopathy with pharmaco-
resistant seizures. Application of RTG partially reversed these effects for the majority of the
analyzed mutations. Thus, RTG or similar drugs have been proposed for use as a person-
alized therapy for this severe disease [210]. But unfortunately toxicity may limit its use, and
there are few data available on its effectiveness in KCNQ2 encephalopathy.
7.2.5. Carbonic anhydrase inhibitors
In humans, 16 different isozymes of the zinc enzyme carbonic anhydrases (CA) have been
described and are considered as drug targets, some of them being involved in various
pathological disorders such as glaucoma, epilepsy, and cancer.
Triggering mechanisms of seizures includes an increase of intracellular potassium concentra-
tion and a pH shift within the brain. pH buffering of extra- and intracellular spaces is mainly
carried out by the CO2/HCO3− buffer, the equilibration of the two species being assured by the
zinc enzyme CA [211]. Neuronal excitability is related to GABAergic depolarization via
GABAA receptor and contributed by HCO3− efflux, playing a role in initiating ictal-like
epileptiform events in several cortical structures. HCO3−-dependent depolarization can be
suppressed by membrane-permeable inhibitors of CA such as acetazolamide, methazolamide,
zonisamide, topiramate, and sulthiame, which can reduce seizures through perturbation of
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the CO2 equilibrium and/or the inhibition of ion channels [212], leading to diminished
depolarization of principal cells and, perhaps, interneurons [213].
• Acetazolamide has been approved for the treatment of epilepsy since 1953, and should be
considered when there is a poor response to conventional antiepileptic drugs or refractory
epilepsy. They have been used in various diseases including LKS [214], dominant paroxys-
mal ataxia, juvenile myoclonic epilepsy, newborn with Arnold-Chiari malformation with
central apneas, or in epileptic apnea in MMPSI resulting in complete disappearance of
epileptic seizures [215].
• Sulthiame is an inhibitor of CA and a widely used add-on antiepileptic drug for the
treatment of intractable epilepsy, WS, status epilepticus during sleep (ESES), continuous
spikes and waves during slow sleep (CSWS) syndrome, and LKS, which was refractory to
other AEDs. Sulthiame may lead to a cessation of seizures when used as an add-on therapy
to pyridoxine in patients with WS. No evidence exists for the use of sulthiame as an add-on
therapy in patients with epilepsy outside WS. Large, multicenter randomized controlled
trials are necessary to inform clinical practice if sulthiame is to be used as an add-on therapy
for epilepsy [216]. Sulthiame was associated with deterioration in cognitive function in
children with benign epilepsy of childhood with central temporal spikes [217].
7.3. Others
7.3.1. Drugs with unknown mechanisms of action
• Levetiracetam (LEV): Although the mechanism of action of LEV is still not well defined,
new hypotheses propose that LEV and brivaracetam act by accelerating the induction of
supply rate depression in synaptic vesicle trafficking, mainly synaptic vesicle glycoprotein
2a (SV2a) during incipient epileptic activity [218]. SV2 (encoded by the SV2A gene -OMIM
185860-) might mediate the uptake of NTs into vesicles. Loss of SV2A leads to a reduction
in action potential-dependent gamma-aminobutyric acid (GABA)ergic neurotransmission
[219]. LEV is utilized for the treatment of seizures, including neonatal seizures. There is
strong evidence that LEV is effective in the treatment of focal seizures, whereas for gener-
alized seizures, there is weak evidence to support the use of levetiracetam, valproate,
lamotrigine, topiramate, and clobazam uses [167]. Treatment with intravenous levetirace-
tam is the new option for patients with refractory status epilepticus, even in patients younger
than 2 years old (off-label use) [220]. Status epilepticus is characterized by downregulation
of the inhibitory gamma-aminobutyric acid system, and LEV acting via different mecha-
nisms could slow the epileptogenesis. Lately, LEV has been considered as the first-choice
treatment for patients with early-onset epileptic encephalopathy due to an STXBP1 mutation
and refractory to other antiepileptic drugs [221, 222].
• Rufinamide is a triazole derivative that is structurally unrelated to any currently marketed
AEDs. It was approved by the FDA in December 2008 for adjunctive treatment of seizures
associated with LGS for children 4 years or older and for adults. The precise mechanism by
which rufinamide exerts its antiepileptic effect is unknown. In vitro studies suggest that the
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principal mechanism of action of rufinamide is modulation of the activity of sodium
channels and, in particular, prolongation of the inactive state of the channel. Placebo‐
controlled studies for rufinamide that have efficacy data include studies involving (1)
patients with LGS in children aged 1 year or older, (2) pediatric partial‐onset seizures as
adjunctive therapy, (3) adult partial‐onset seizures (for both monotherapy and adjunctive
therapy), and (4) patients with refractory GTCs [223]. Few studies in children with epileptic
encephalopathies (EE) aged <4 years show that RUF is efficacious (60% were responders)
and well tolerated. Therefore, for controlling seizures in this very severe form of epilepsy,
the off‐label use of RUF is justified [224].
7.3.2. Steroid hormones and neurosteroids
Steroid hormones and neurosteroids play an important role in children and adults with
epilepsy, and act on both synaptic and extrasynaptic GABAA receptors. Corticosteroids,
progesterone, estrogens, and neurosteroids have been shown to affect seizure activity in animal
models and in clinical studies (for a review, see [225]).
• Sex-steroid hormones influence brain excitability and could explain sex differences in
seizure susceptibility. Androgens are mainly anticonvulsant (mainly enhance GABA‐
activated currents), but the effects are more varied. For the female gender, progesterone and
its metabolites are anticonvulsant, while estrogens are mainly proconvulsant (e.g., catame‐
nial epilepsy). Estrogens reduce chloride conductance and potentiate glutamate receptor‐
mediated excitotoxicity responses (by potentiating NMDA receptor activity), but also affect
GABAergic mechanisms and alter brain morphology by enhancing the density dendrite
spine. Progesterone is a natural endogenous anticonvulsant hormone with substantial
impact on seizure susceptibility that acts mainly to enhance postsynaptic GABAergic
activity by increasing chloride conductance at GABAA receptors and attenuates the gluta‐
mate excitatory response. It also alters messenger RNA for glutamic acid decarboxylase
and GABAA receptor subunits (for a review, see [226]).
• Adrenocorticotrophic hormone and oral corticosteroids: Pituitary‐adrenal hormones have
long been known to affect epileptogenesis. Even though the mechanism behind the efficacy
of ACTH is mediated by biochemical processes that remain unknown, a reduction in
glutamine/glutamate levels in the cerebral cortex after ACTH therapy in patients with WS
has been shown [227]. Systemic administration of ACTH causes an increase in midbrain and
striatal GABA receptor binding [228]. ACTH, oral corticosteroids, and VGB are now first‐
line treatments for IS in the United States and Europe. The current literature suggests that
short‐term, low‐dose ACTH (versus high dose) should be considered first‐line treatment
of IS [229], and is more effective than oral corticosteroids and VGB for the cessation of
spasms. ACTH is preferred for short‐term control of epileptic spasms not due to tuberous
sclerosis (level B recommendation). Oral steroids are probably effective in short‐term control
of spasms (level C recommendation), and a shorter interval from the onset of spasms to
treatment initiation may improve long‐term neurodevelopmental outcome (level C recom‐
mendation) [167]. Nevertheless, some clinicians use corticosteroids, VGB, and TPM as first‐
line treatments for this group. As we have already mentioned above, initial combined
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treatment with low-dose ACTH and TPM was effective in treating ISS in most patients. After
removing ACTH from the treatment regimen, TPM can be left as the AED of choice to
prevent recurrence of the ISS. For refractory infantile spasms, other antiepileptic drugs have
been used (i.e., valproate, zonisamide, sulthiame, levetiracetam, lamotrigine, pyridoxine,
and ganaxolone) as well as adjunctive flunarizine and novel drugs not yet in clinical use
(i.e., pulse rapamycin and melanocortin receptor agonists) [230].
• Neurosteroids: Ganaxolone (GNX) is the 3-beta-methylated synthetic analog of allopreg-
nanolone; it belongs to a class of compounds referred to as neurosteroids. GNX is an
allosteric modulator of GABA(A) receptors, acting through binding sites, which are distinct
from the benzodiazepine-binding site [231]. In children with refractory ISS, or with con-
tinuing seizures after a prior history of ISS, ganaxolone has been used as a second-line drug
[232].
7.3.3. Other drugs
• Quinidine reverses the in vitro functional gain seen with KCNT1 mutations implicated in
EIEE 14, and a clinical response to quinidine has been observed [233, 234].
• Rapamycin: The recent discovery of the importance of mutations in DEPDC5 (OMIM
614191, “Dep domain-containing protein 5”) for familial focal epilepsy with variable foci
(OMIM 604364), associated with both lesional (focal cortical dysplasia, band heterotopia,
hemimegalencephaly, etc.) and non-lesional epilepsies, whose expression occurred through-
out neurons and GABAergic interneurons in brain development, has provided a new source
for therapeutic targets. Since DEPDC5 is now known to be a regulator of the mTOR
(mammalian target of rapamycin) pathway, this raises the possibility of treatment with
rapamycin analogs [235]. Modulation of the mammalian target of rapamycin pathway may
hold promise for malformation-associated epilepsy. All of these observations will need
careful double-blind trials to establish efficacy [236].
• Potassium bromide, an old antiepileptic drug, should have a place as a drug of tertiary
choice in the treatment of children with refractory epilepsy. Its main use is in the treatment
of MMPS [237] and Dravet’s syndrome [238].
8. Conclusion
The distinction between early infantile epileptic encephalopathy (EIEE) —mostly known as
Ohtahara syndrome—and early myoclonic encephalopathy (EME), unfortunately, is not
always easy due to clinical and etiological overlap. Thus, different authors suggest that both
entities are actually the same entity.
The main differences lie in the type of crisis, which may correspond with the underlying
activity of the GABAergic system. Acute noxa in the newborn with a still immature cortical
brain produces a strong release of GABA. Due to the more depolarized Cl− reversal potential
in the neonatal neurons, the binding of GABA to ligand-gated GABAA receptor-associated Cl
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− channels triggers Cl− efflux and a depolarizing excitation leading to severe and early myo-
clonic seizures. However, when impairments in the proper migration of GABAergic inter-
neurons occur, a longer period without epileptogenic activity would be expected. Tonic
seizures would appear later associated with the severity of the brainstem dysfunction.
According to this view, this second type would not be so much an “age-dependent encephal-
opathy” but rather a “damage-dependent encephalopathy”. Therefore, it is possible that these
syndromes represent different stages of a progressive neuronal-dysfunction epileptic “con-
tinuum of pathology” with a suppression-burst pattern.
A greater knowledge of the genes involved in the origins of epilepsy may lead to a future
with improved treatments for patients with early encephalopathies.
Nomenclature/abbreviations
ACTH adrenocorticotrophic hormone
ADNFLE autosomal dominant nocturnal frontal lobe epilepsy
AEDs antiepileptic drugs
AMPA alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid
ARX aristaless-related homeobox gene
Array-CGH array-comparative genomic hybridization
ASDs autism spectrum disorders
BFNS1 benign familial neonatal seizures-1
BFIS3 benign familial infantile seizures-3
BLBP brain lipid-binding protein
BS burst suppression
CA carbonic anhydrases
CAE childhood absence epilepsy
CBZ carbamazepine
CLB clobazam
CNS central nervous system
CNVs copy number variations
CSWS continuous spikes and waves during sleep
DS Dravet’s syndrome
EAA excitatory amino acids
EEG electroencephalogram
EEs epileptic encephalopathies
EIEE early infantile epileptic encephalopathy
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EEIE early epileptic infantile encephalopathy
EIMFS epilepsy of infancy with migrating focal seizures
EME early myoclonic encephalopathy
EOEEs early-onset epileptic encephalopathies
ESES status epilepticus during sleep
ESM ethosuximide
EZG ezogabine
GABA gamma-aminobutyric acid
GABAARs GABA subtype A receptor channel chloride currents
GABA-T GABA aminotransferase
GBP gabapentin
GNX ganaxolone
GPI glycosylphosphatidylinositol
GTCs generalized tonic-clonic seizures
HIE hypoxic-ischemic encephalopathy
iGluRs ionotropic glutamate receptors
ID intellectual disability
ILAE International League Against Epilepsy
ISS infantile spasms
LCRs low-copy repeats
LGS Lennox-Gastaut syndrome
LKS Landau-Kleffner syndrome
LTG lamotrigine
MEI myoclonic epilepsy in infancy
mGlu metabotropic glutamate
MMPSI malignant migrating partial seizures in infancy
MRI magnetic resonance imaging
NAHR non-allelic homologous recombination
NBs newborns
NMDA N-methyl-D-aspartic acid
NS nervous system
NSID nonsyndromic intellectual disability
NT neurotransmitters
OLs oligodendrocytes
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OMIM online Mendelian inheritance in man
OS Ohtahara syndrome
OXC oxcarbazepine
PER perampanel
PB phenobarbital
PCW postconceptional weeks
PHT phenytoin
RTG retigabine
SBP suppression-burst patterns
SDs segmental duplication
SLC25A22 solute carrier family 25, member 22 gene
SMEN severe myoclonic epilepsy in infancy
STN subthalamic nucleus
SPZ subplate zone
STP stiripentol
S- XLMR syndromic X-linked mental retardation
TARPs transmembrane AMPA regulatory proteins
TGB tiagabine
TPM topiramate
VPA sodium valproate
VGB vigabatrin
WM white matter
WS West syndrome
XLMR X-linked mental retardation
ZNS zonisamide
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